Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 000-53832

MALACHITE INNOVATIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada

75-3268988

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

200 Park Avenue, Suite 400
Cleveland, OH		44122
(Address of principal executive offices)		(Zip Code)

(216) 304-6556

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol		Name of each exchange on which registered:
Common Stock		MLCT		OTC Markets

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 1, 2023, there were 80,850,148 shares of the registrant’s common stock outstanding.

MALACHITE INNOVATIONS, INC.

Quarterly Report on Form 10-Q

For the Quarterly Period Ended

June 30, 2023

INDEX

PART I - FINANCIAL INFORMATION	3

Item 1. Financial Statements	3
Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022	4
Consolidated Unaudited Statements of Operations for the Three and Six Months Ended June 30, 2023 and June 30, 2022	5
Consolidated Unaudited Statements of Changes in Stockholders’ Equity (Deficit) for the Three and Six Months Ended June 30, 2023 and June 30, 2022	6
Consolidated Unaudited Statements of Cash Flows for the Six Months Ended June 30, 2023 and June 30, 2022	7
Notes to the Consolidated Unaudited Financial Statements	8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3. Quantitative and Qualitative Disclosures About Market Risk	31
Item 4. Controls and Procedures	31

PART II - OTHER INFORMATION	32

Item 1. Legal Proceedings	32
Item 1A. Risk Factors	32
Item 6. Exhibits	32

SIGNATURES	33

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

MALACHITE INNOVATIONS, INC.

CONSOLIDATED FINANCIAL STATEMENTS

THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022

CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2023 AND DECEMBER 31, 2022	4

CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND JUNE 30, 2022	5

CONSOLIDATED UNAUDITED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND JUNE 30, 2022	6

CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND JUNE 30, 2022	7

NOTES TO THE CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS	8

MALACHITE INNOVATIONS, INC.

CONSOLIDATED BALANCE SHEETS

	June 30, 2023			December 31, 2022
	(Unaudited)			(Audited)
Assets

Current Assets
Cash and cash equivalents	$	359,564		$	442,369
Accounts receivable		1,273,635			981,385
Unbilled receivables		1,129,046			-
Prepaid expenses		47,719			884
Total current assets		2,809,964			1,424,638
Long-term Assets
Equipment, net of accumulated depreciation		6,134,119			6,045,514
Goodwill		751,421			751,421
Deposits		19,976			8,892
Total long-term assets		6,905,516			6,805,827
Total Assets	$	9,715,480		$	8,230,465

Liabilities and Stockholders’ Equity

Current Liabilities
Accounts payable	$	772,892		$	233,808
Current portion of long-term debt		1,089,509			1,319,201
Line of credit		1,200,000			-
Total current liabilities		3,062,401			1,553,009
Long-term Liabilities
Long-term debt, net of current portion		3,457,814			3,738,013
Total long-term debt		3,457,814			3,738,013
Total liabilities		6,520,215			5,291,022

Stockholders’ Equity
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 80,850,148 and 78,116,814 shares issued and outstanding, respectively		80,850			78,117
Additional paid-in-capital		53,517,367			53,074,180
Accumulated deficit		(50,402,952	)		(50,212,854	)
Total stockholders’ equity		3,195,265			2,939,443
Total Liabilities and Stockholders’ Equity	$	9,715,480		$	8,230,465

See accompanying notes to the consolidated financial statements.

MALACHITE INNOVATIONS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	2023			2022			2023			2022
	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Revenues	$	3,998,267		$	639,359		$	7,013,154		$	639,359
Cost of services		3,153,166			574,407			5,519,051			574,407
Gross profit		845,101			64,952			1,494,103			64,952

Operating expenses:
General and administrative		635,898			380,326			1,361,946			698,267
Research and development		107,444			107,823			213,621			233,553
Total operating expenses		743,342			488,149			1,575,567			931,820

Income (loss) from operations		101,759			(423,197	)		(81,464	)		(866,868	)

Other expenses:
Interest expense		(64,997	)		(19,989	)		(108,634	)		(24,292	)
Other income		-			-			-			-
Total other expenses, net		(64,997	)		(19,989	)		(108,634	)		(24,292	)

Net income (loss)	$	36,762		$	(443,186	)	$	(190,098	)	$	(891,160	)

Basic and diluted income (loss) per common share	$	0.00		$	(0.01	)	$	(0.00	)	$	(0.02	)
Earnings per share, basic	$	0.00		$	(0.01	)	$	(0.00	)	$	(0.02	)
Weighted average number of common shares outstanding:
Basic and diluted		80,519,745			65,406,191			79,324,917			58,466,722
Weighted average number of shares outstanding, basic		80,519,745			65,406,191			79,324,917			58,466,722

See accompanying notes to the consolidated financial statements.

MALACHITE INNOVATIONS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022

(Unaudited)

	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Total
	Three months ended June 30, 2023
	Common Stock				Additional
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Total
Balance as of March 31, 2023		78,116,814	$	78,117	$	53,074,180	$	(50,439,714	)	$	2,712,583
Shares issued for cash		2,733,334		2,733		407,267		-			410,000
Fair value of vested stock options		-		-		35,920		-			35,920
Net income		-		-		-		36,762			36,762
Balance as of June 30, 2023		80,850,148	$	80,850	$	53,517,367	$	(50,402,952	)	$	3,195,265
Balance		80,850,148	$	80,850	$	53,517,367	$	(50,402,952	)	$	3,195,265

	Three months ended June 30, 2022
	Common Stock				Additional
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Total
Balance as of March 31, 2022		51,450,147	$	51,450	$	48,707,587	$	(49,588,652	)	$	(829,615	)
Balance		51,450,147	$	51,450	$	48,707,587	$	(49,588,652	)	$	(829,615	)
Shares issued for cash		20,000,000		20,000		2,980,000		-			3,000,000
Shares issued in exchange for Range		5,000,000		5,000		745,000		-			750,000
Net loss		-		-		-		(443,186	)		(443,186	)
Balance as of June 30, 2022		76,450,147	$	76,450	$	52,432,587	$	(50,031,838	)	$	2,477,199
Balance		76,450,147	$	76,450	$	52,432,587	$	(50,031,838	)	$	2,477,199

	Six months ended June 30, 2023
	Common Stock				Additional
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Total
Balance as of December 31, 2022		78,116,814	$	78,117	$	53,074,180	$	(50,212,854	)	$	2,939,443
Balance		78,116,814	$	78,117	$	53,074,180	$	(50,212,854	)	$	2,939,443

Shares issued for cash		2,733,334		2,733		407,267		-			410,000
Fair value of vested stock options		-		-		35,920		-			35,920
Net loss		-		-		-		(190,098	)		(190,098	)
Balance as of June 30, 2023		80,850,148	$	80,850	$	53,517,367	$	(50,402,952	)	$	3,195,265
Balance		80,850,148	$	80,850	$	53,517,367	$	(50,402,952	)	$	3,195,265

	Six months ended June 30, 2022
	Common Stock				Additional
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Total
Balance as of December 31, 2021		51,450,147	$	51,450	$	48,707,587	$	(49,140,678	)	$	(381,641	)
Balance		51,450,147	$	51,450	$	48,707,587	$	(49,140,678	)	$	(381,641	)
Shares issued for cash		20,000,000		20,000		2,980,000		-			3,000,000
Shares issued in exchange for Range		5,000,000		5,000		745,000		-			750,000
Net loss		-		-		-		(891,160	)		(891,160	)
Net income ( loss)		-		-		-		(891,160	)		(891,160	)
Balance as of June 30, 2022		76,450,147	$	76,450	$	52,432,587	$	(50,031,838	)	$	2,477,199
Balance		76,450,147	$	76,450	$	52,432,587	$	(50,031,838	)	$	2,477,199

See accompanying notes to the consolidated financial statements.

MALACHITE INNOVATIONS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	2023			2022
	Six Months Ended June 30,
	2023			2022
Cash flows from operating activities:
Net loss	$	(190,098	)	$	(891,160	)

Adjustments to reconcile net loss to net cash used in operating activities:
Fair value of vested stock options		35,920			-
Depreciation		695,910			55,392
Changes in operating assets and liabilities:
Accounts receivable		(292,250	)		273,412
Unbilled receivables		(1,129,046	)		(230,929	)
Interest accrued but not paid		-			2,789
Due from shareholder		-			(250,000	)
Prepaid expense and other current assets		(46,835	)		3,000
Accounts payable and accrued liabilities		539,084			192,628
Deposits		(11,084	)		(200	)
Net cash used in operating activities		(398,399	)		(845,068	)

Cash flows from investing activities:
Equipment purchases		(784,515	)		(1,107,833	)
Cash acquired in acquisition of Range Environmental Resources		-			15,827
Cash paid for acquisition of Range Environmental Resources		-			(750,000	)
Net cash used in investing activities		(784,515	)		(1,842,006	)

Cash flows from financing activities:
Issuance of shares for cash		410,000			3,000,000
Proceeds from long-term debt		383,202			1,015,020
Repayment of long-term debt		(893,093	)		-
Proceeds from line of credit		1,200,000			500,000
Net cash provided by financing activities		1,100,109			4,515,020

Net increase (decrease) in cash and cash equivalents		(82,805	)		1,827,946

Cash and cash equivalents - beginning of period		442,369			38,343
Cash and cash equivalents - end of period	$	359,564		$	1,866,289

Supplemental disclosure of cash flow information:
Cash paid during the period for:
Interest	$	108,634		$	21,503
Stock issued for acquisition		-			750,000
Income taxes		-			-

See accompanying notes to the consolidated financial statements.

MALACHITE INNOVATIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022

(Unaudited)

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Malachite Innovations, Inc. (the “Company”, “we”, “us”, “our” or “Malachite”), was incorporated in the State of Nevada on June 29, 2007. Malachite is a public holding company dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Malachite owns and operates a balanced portfolio of operating businesses focused on developing long-term solutions to environmental, social and health challenges, with a particular focus on economically disadvantaged communities. Malachite takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Malachite seeks to thoughtfully allocate its capital into ventures that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for our shareholders.

Originally founded in 2007 as Legend Mining Inc., the Company began operations as a mineral extraction exploration business. In 2011, the Company changed its name to Stevia First Corp. and pursued a new strategy focused on developing stevia-based additives for the food and beverage industry. In 2015, the Company changed its name to Vitality Biopharma, Inc. and pursued a new strategy focused on developing cannabinoid-based prodrugs anticipated to treat inflammatory conditions of the gastrointestinal tract by unlocking the therapeutic properties of cannabinoids but without their unwanted psychoactive side effects.

In October 2021, the Company changed its name to Malachite Innovations, Inc. and reorganized its corporate structure and created the following two wholly-owned operating subsidiaries: (i) Graphium Biosciences, Inc., a Nevada corporation (“Graphium”), into which the Company contributed all of its drug development assets; and (ii) Daedalus Ecosciences, Inc., a Nevada corporation (“Daedalus”) which was formed to serve as a holding company for the Company’s future impact investing operating businesses.

In May 2022, Daedalus acquired Range Environmental Resources, Inc., a West Virginia corporation (“Range Environmental”) and Range Natural Resources, Inc., a West Virginia corporation (“Range Natural” and together with Range Environmental, the “Range Reclamation Entities”). The Range Reclamation Entities provide land reclamation, water restoration and environmental consulting services to mining and non-mining customers throughout the Appalachian region with the goal of returning land to pre-mining conditions or repurposing the land for natural, commercial, agricultural or recreational use. The Range Reclamation Entities’ water restoration services seek to improve rivers, streams and discharges through novel and innovative treatment applications to help customers meet their various regulatory standards and requirements. The Range Reclamation Entities also provide environmental consulting services to customers typically in connection with land reclamation and water restoration projects and as an additional value-add service, sells water treatment chemicals manufactured by third parties to their customers. Range Natural also provides resource mining services for customers incidental to the reclamation and repurposing of mine sites.

On December 31, 2022, Daedalus was merged into Malachite Innovations, Inc., leaving Malachite Innovations, Inc., as the parent company and the Range Reclamation Entities, Aether Credit Ventures, Inc., NextGen AgriTech, Inc., Pristine Stream Ventures, Inc., Range Security Resources, Inc., Terra Preta, Inc. and Graphium as its wholly-owned subsidiaries.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, during the six months ended June 30, 2023, the Company incurred a net loss of $190,098 and used $398,399 of cash in the Company’s operating activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. The Company estimates, as of June 30, 2023, that it has sufficient funds to operate the business for 12 months given its cash balance of $359,564, line of credit availability of $800,000, and revenues being generated by the Range Reclamation Entities. Although the Company’s existing cash balances are estimated to be sufficient to fund its currently planned level of operations, the Company is actively seeking additional financing and other sources of capital to accelerate the funding and execution of its growth strategy and value creation plan. However, these estimates could differ if the Company encounters unanticipated difficulties, or if its estimates of the amount of cash necessary to operate its business prove to be wrong, and the Company uses its available financial resources faster than it currently expects. No assurance can be given that any future financing or capital, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company.

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Aether Credit Ventures, Inc., Graphium Biosciences, Inc., NextGen AgriTech, Inc., Pristine Stream Ventures, Inc., Range Environmental Resources, Inc., Range Natural Resources, Inc., Range Security Resources, Inc., Terra Preta, Inc., and Daedalus Ecosciences, Inc. (merged into Malachite Innovations, Inc. on December 31, 2022), and have been prepared in accordance with accounting principles generally accepted in the United States of America. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Revenue Recognition

The Company recognizes revenue under ASC 606, “Revenue from Contracts with Customers”. The core principle of the revenue standard is that a company should recognize revenue by analyzing the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) each performance obligation is satisfied. The Company primarily invoices customers and recognizes revenue on a periodic basis for equipment and labor hours provided to a customer on a particular job based on an agreed-upon hourly rate sheet or a fixed amount for a project. The Company also invoices customers and recognizes revenue for equipment mobilization fees and materials and supplies required to complete a project. The Company invoices for the sales of chemicals and recognizes revenue when the products are delivered to the customer’s designated site. Costs for equipment, labor and chemicals are generally expensed as incurred since the projects are generally short-term and not subject to a contract. The Company also invoices customers for the provision of environmental security services on an agreed-upon hourly rate for each project. All revenue is recognized at a point in time.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances.

Accounts Receivable

Trade accounts receivable are stated at the amount management expects to collect from the balances outstanding at the end of each fiscal period reflected in the consolidated balance sheets. Based on management’s assessment, it has concluded that losses on balances outstanding as of those dates will be immaterial and, therefore, no allowances were recorded for the three months ended June 30, 2023 or the three months ended June 30, 2022. Accounts receivable were $1,273,635 and $981,385 at June 30, 2023 and December 31, 2022, respectively. No bad debt expense was accrued in either the three months ended June 30, 2023 or the three months ended June 30, 2022 and there is no allowance for doubtful accounts as of June 30, 2023 or December 31, 2022.

Unbilled Receivables

Unbilled receivables represent revenue that has been recognized on projects for which billings have not been presented to the customer because the amounts were earned but not billable at the balance sheet date.

Equipment

Equipment is carried at cost. Expenditures for maintenance and repairs are charged to cost of services. Additions and betterments are capitalized. The cost and related accumulated depreciation of equipment sold or otherwise disposed of are removed from the accounts and any gain or loss is reflected in the current year’s earnings.

SCHEDULE OF EQUIPMENT

	June 30, 2023		December 31, 2022

Equipment	$	7,422,329	$	6,637,814
Accumulated depreciation		1,288,210		592,300
Net book value		6,134,119		6,045,514
Depreciation expense	$	695,910	$	395,543

The Company provides for depreciation of equipment using the straight-line method for both financial reporting and federal income tax purposes over the estimated six-year useful lives of the equipment.

The Company assesses the recoverability of its equipment by determining whether the depreciation of the assets over their remaining lives can be recovered through projected future cash flows generated by the assets. There were no assets identified for impairment.

Delivery Costs

Delivery costs are classified as cost of sales.

Goodwill

Goodwill is tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not (i.e., a likelihood greater than 50%) that the intangible asset is impaired.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.

Leases

The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. As of June 30, 2023, the Company had no lease commitments for longer than one year.

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Consolidated Statements of Operations with classification depending on the nature of the services rendered.

The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Basic and Diluted Income (Loss) Per Share

Basic income (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted income (loss) per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted income (loss) per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

	June 30, 2023		December 31, 2022
Options		9,792,544		9,392,544
Warrants		25,046,669		22,313,335
Total		34,839,213		31,705,879
Anti-dilutive loss per shares		34,839,213		31,705,879

Patents and Patent Application Costs

Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Accordingly, patent costs are expensed as incurred.

Research and Development

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.

Fair Value of Financial Instruments

FASB ASC 825, “Financial Instruments” requires that the Company disclose estimated fair values of financial instruments. Financial instruments held by the Company include, among others, accounts receivable, accounts payable and long-term debt. The carrying amounts reported in the balance sheets for assets and liabilities qualifying as financial instruments are a reasonable estimate of fair value.

Segments

As of June 30, 2023, the Company has five operating business segments: (i) Environmental Services, (ii) Biochar Products and Solutions, (iii) Stream Mitigation Banking, (iv) Environmental Security Services, and (v) Cannabinoid Drug Development. In October 2021, the Company began operating under two segments: (i) Graphium Biosciences, Inc., a wholly-owned subsidiary of the Company, reports the operating results of our cannabinoid drug development segment, which is advancing a broad portfolio of glycosylated cannabinoid prodrugs that have been developed to unlock the rebalancing effects of the endocannabinoid system to address numerous chronic conditions, and (ii) the Range Reclamation Entities, which are wholly-owned subsidiaries of the Company, report the operating results of the Environmental Services segment, which provides land reclamation, water restoration and environmental consulting services to mining and non-mining customers. The Biochar Products and Solutions, Stream Mitigation Banking, and Environmental Security Services business segments began operations in the first quarter of 2023.

In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 was effective for the Company beginning January 1, 2023. This did not have a material effect on the Company’s financial position, results of operations, or cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

2. ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES

In May 2022, the Company and its wholly-owned subsidiary, Daedalus Ecosciences, Inc., entered into a share purchase agreement with Range Environmental Resources, Inc. (“Range Environmental”), and Range Natural Resources, Inc. (“Range Natural”, and collectively with Range Environmental, the “Range Reclamation Entities”), and the two (2) shareholders of the Range Reclamation Entities (the “Range Shareholders”) (the “Share Purchase Agreement”), under which the Company issued a total of 10,000,000 shares of the Company’s common stock to the Range Shareholders and Daedalus Ecosciences paid cash consideration of $1,000,000 to the Range Shareholders for 80% of the outstanding common stock of each of the Range Reclamation Entities.

Subsequent to entering into the Share Purchase Agreement, the Company discovered that Joshua Justice, one of the Range Shareholders (“Justice”), made certain misrepresentations in the Share Purchase Agreement. On July 12, 2022, the Company entered into a Separation Agreement, by and among the Company, Daedalus Ecosciences, the Range Reclamation Entities, and Justice and his spouse (the “Separation Agreement”) pursuant to which Justice: a) acknowledged that his employment with the Range Reclamation Entities was terminated for cause effective June 30, 2022; b) returned the 5,000,000 shares of the Company’s common stock that had been issued to him under the terms of the Share Purchase Agreement; c) transferred his 10% interest in each of the Range Reclamation Entities to Daedalus Ecosciences; and d) paid Daedalus Ecosciences cash in an amount of $250,000. As a result, only 5,000,000 of the Company’s common stock issued to the Range Shareholders is considered to have been issued in exchange for 90% of the outstanding common stock of each of the Range Reclamation Entities.

Subsequently, on October 11, 2022, Daedalus Ecosciences and Jeremy Starks, the remaining Range Shareholder (“Starks”), entered into a share purchase agreement, effective as of May 11, 2022 (the “Starks Agreement”), pursuant to which Starks exchanged his 10% common stock ownership of the Range Reclamation Entities for 10% of the Cash Dividends and Sale Proceeds (as both terms are defined in the Starks Agreement) of the Range Reclamation Entities. As a result of the merger of Daedalus Ecosciences into Malachite as of December 31, 2022, the Range Reclamation Entities are reported as wholly-owned subsidiaries of the Company in the financial statements made part of this Form 10-Q. No other changes were made to the consideration received by Starks as part of the Share Purchase Agreement and he remains as President of each of the Range Reclamation Entities.

The Company accounted for the transaction as a business combination in accordance ASC 805 “Business Combinations”. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed. The fair values of the assets acquired are set forth below. The allocation of the purchase price is based on management’s estimates.


Fair value of assets acquired:
Cash	$	15,827
Accounts receivables		889,919
Property and equipment		628,000
Goodwill		751,421
Total assets acquired		2,285,167
Fair value of liabilities assumed		(785,167	)
Purchase price	$	1,500,000
Cash consideration		750,000
Common stock consideration		750,000
Total purchase price	$	1,500,000
Acquisition transaction costs incurred	$	20,592

Goodwill has an assigned value of $751,421 and represents the value of the Range Reclamation Entities’ brand reputation, customer base and employee relations.

3. GOODWILL

Goodwill was $751,421 at June 30, 2023 and at December 31, 2022. The goodwill as of both dates represents the value of the Range Reclamation Entities’ employee relations. Goodwill by reportable segment is as follows:

SCHEDULE OF GOODWILL

	June 30, 2023		December 31, 2022
Environmental Services:
Beginning Balance	$	751,421	$	-
Acquisitions		-		751,421
Adjustments		-		-
Ending Balance	$	751,421	$	751,421

4. EQUITY

Issuance of Common Stock and Warrants

On April 11, 2023, the Company entered into securities purchase agreements providing for the issuance and sale by the Company of (i) 2,733,334 shares of the Company’s common stock (the “Shares”) at a price of $0.15 per share and (ii) warrants to purchase up to an additional 2,733,333 shares of the Company’s common stock (the “Warrants”, and the shares issuable upon exercise of the Warrant, the “Warrant Shares”) at a price of $0.60 per share. The Warrants expire on April 11, 2028. The aggregate proceeds to the Company from the sale of the Shares and Warrants were approximately $400,000.

5. STOCK OPTIONS

Stock options issued during the three months ended June 30, 2023 and the three months ended June 30, 2022

During the three months ended June 30, 2023, the Company granted options to two outside advisors to purchase an aggregate of 400,000 shares of the Company’s common stock with exercise prices of $0.18 per share that expire five years from the date of grant. Options to purchase 200,000 shares vested upon grant and options to purchase 200,000 vest over two years. The fair value of each option award was estimated on the date of grant using the Black-Scholes-Merton Option Pricing model based on the following assumptions: (i) volatility rate between 273.24% and 273.87%, (ii) discount rate between 1.4% and 1.55%, (iii) zero expected dividend yield, and (iv) expected life of 5 years, which is the term of the options. The total fair value of the option grants at their grant dates was approximately $71,840, $35,920 of which was allocated to general and administrative expenses during the three months ended June 30, 2023.

No stock options were granted to directors, advisors, and employees during the three months ended June 30, 2022.

During the three months ended June 30, 2023, total stock-based compensation expense related to vested stock options was $35,920. During the three months ended June 30, 2022, the Company recorded no stock-based compensation expense related to vested stock options. At June 30, 2023, the remaining unamortized cost of the outstanding stock-based awards was approximately $35,920 and will be amortized on a straight-line basis over the remaining vesting period of 2 years.

A summary of the Company’s stock option activity during the six months ended June 30, 2023 is as follows:

SUMMARY OF STOCK OPTION ACTIVITY

	Shares		Weighted Average Exercise Price
Balance outstanding at December 31, 2022		9,392,544	$	0.54
Granted		400,000		0.18
Exchanged		-		-
Exercised		-		-
Expired		-		-
Forfeited		-		-
Balance outstanding at June 30, 2023		9,792,544	$	0.52
Balance exercisable at June 30, 2023		9,592,544	$	0.53

At June 30, 2023, the 9,792,544 outstanding stock options had no intrinsic value.

A summary of the Company’s stock options outstanding as of June 30, 2023 is as follows:

SCHEDULE OF STOCK OPTION OUTSTANDING

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- Date Stock Price
Options Outstanding, June 30, 2023		3,050,000	$	0.18	$	0.18
		1,150,000	$	0.277	$	0.277
		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		350,834	$	1.50 - 1.95	$	1.50 - 1.95
		597,500	$	2.00 - 2.79	$	2.00 - 2.79
		83,334	$	3.10 - 3.80	$	3.10 - 3.80
		18,334	$	4.00 - 4.70	$	4.00 - 4.70
		9,792,544

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2023 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- Date Stock Price
Options Outstanding and Exercisable, June 30, 2023		2,850,000	$	0.18	$	0.18
		1,150,000	$	0.277	$	0.277
		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		350,834	$	1.50 - 1.95	$	1.50 - 1.95
		597,500	$	2.00 - 2.79	$	2.00 - 2.79
		83,334	$	3.10 - 3.80	$	3.10 - 3.80
		18,334	$	4.00 - 4.70	$	4.00 - 4.70
		9,592,544

6. WARRANTS

A summary of warrants to purchase common stock issued during the six months ended June 30, 2023 is as follows:

SCHEDULE OF WARRANTS ACTIVITY

	Shares		Weighted Average Exercise Price
Balance outstanding at December 31, 2022		22,313,335	$	0.61
Granted		2,733,334		0.60
Exercised		-		-
Expired		-		-
Balance outstanding and exercisable at June 30, 2023		25,046,669	$	0.61

At June 30, 2023, the 25,046,669 outstanding stock warrants had no intrinsic value.

7. LINES OF CREDIT

In November 2022, the Company secured a bank line of credit with a limit of $1,000,000. The line of credit expires on November 30, 2023 and bears interest at one percent (1%) above the prime rate (9.25% at June 30, 2023). As of June 30, 2023, the balance due under the line of credit was $200,000.

In June 2023, the Range Reclamation Entities secured a separate bank line of credit with a limit of $1,000,000. This line of credit is secured by all of the Range Reclamation Entities’ fixed assets. This line of credit expires on June 24, 2024 and bears interest at the prime rate (8.25% at June 30, 2023). As of June 30, 2023, the balance due under this line of credit was $1,000,000.

8. LONG-TERM DEBT OBLIGATIONS

Long-term debt consists of debt on vehicles and equipment, which serves as the collateral. Interest rates range from 3.69% to 9.95% for 2023. The debt matures from 2023 through 2028.

A summary of payments due under the long-term debt by year is as follows:


2023 – due between July 1, 2023 and June 30, 2024	$	1,089,509
2024 – due between July 1, 2024 and June 30, 2025		1,133,938
2025 – due between July 1, 2025 and June 30, 2026		768,744
2026 – due between July 1, 2026 and June 30, 2027		756,993
2027 – due between July 1, 2027 and June 30, 2028		626,976
2028 and later – due on July 1, 2028 and thereafter		171,163
Total long-term debt	$	4,547,323

9. MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK

Sales to the Company’s largest customer were 94% and 92% of total sales for the three months ended June 30, 2023 and the six months ended June 30, 2023, respectively. Sales to the Company’s two largest customers were 91% of total sales for the three and six months ended June 30, 2022.

Accounts receivable from the same customer were 96% of total accounts receivable and unbilled receivables as of June 30, 2023. Accounts receivable from the Company’s two largest customers were 93% of total accounts receivable and unbilled receivables as of June 30, 2022.

10. COMMITMENTS AND CONTINGENCIES

The Company received a letter in February 2021 from counsel for the Company’s director’s and officer’s insurance carrier (the “insurer”) demanding that the Company reimburse the insurer for sums advanced by the insurer to a former director of the Company as defense costs in connection with a claim purportedly arising under a previous directors and officers insurance policy. The Company believes it has no liability for this claim on the basis of, among other things, Nevada law, the Company’s governing documents and the language of the policy. Accordingly, as of June 30, 2023, no contingent liability has been recorded in the Company’s consolidated statements of financial condition for this matter.

11. SEGMENT INFORMATION

ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about services, categories, business segments and major customers in financial statements. The Company has five reportable segments that are based on the following business units: (i) Environmental Services, (ii) Biochar Products and Solutions, (iii) Stream Mitigation Banking, (iv) Environmental Security Services, and (v) Cannabinoid Drug Development. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes.

The five reportable segments that result from applying the aggregation criteria are as follows:

●	Environmental Services – land reclamation, water restoration and environmental consulting services

●	Biochar Products and Solutions - biochar product development and environmental solutions business

●	Stream Mitigation Banking – mitigation banks to restore waterways and support economic development

●	Environmental Security Services – security services on mines transitioning to next generation industries

●	Cannabinoid Drug Development – glycosylated cannabinoid drug development program

The Company operated two reportable business segments during the three and six months ended June 30, 2022, the Cannabinoid Drug Development and Environmental Services segments. The other business segments began operating in 2023.

The Company had no inter-segment sales for the periods presented.

Summarized financial information concerning the Company’s reportable segments is shown as below:

By Categories

	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total
	For the three months ended June 30, 2023
	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total

Sales	$	3,882,492	$	-			-	$	115,775	$	-		$	-		$	3,998,267
Cost of services		3,092,805		-			-		60,361		-			-			3,153,166
Gross profit		789,687		-			-		55,414		-			-			845,101
Net income (loss)		433,922		(19,116	)		-		37,550		(107,444	)		(308,150	)		36,762

Total assets		9,440,020		15,138			-		94,610		8,784			156,928			9,715,480
Depreciation		338,409		426			-		2,891		-			-			341,726
Interest expense		63,061		-			-		224		-			1,712			64,997
Tax expense		-		-			-		-		-			-			-
Capital expenditures for long-lived assets	$	38,289	$	-			-	$	-	$	-		$	-		$	38,289

	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total
	For the six months ended June 30, 2023
	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total

Sales	$	6,870,979	$	-			-	$	142,175	$	-		$	-		$	7,013,154
Cost of services		5,442,713		-			-		76,338		-			-			5,519,051
Gross profit		1,428,266		-			-		65,837		-			-			1,494,103
Net income (loss)		620,565		(38,280	)		-		20,445		(213,621	)		(579,207	)		(190,098	)

Total assets		9,440,020		15,138			-		94,610		8,784			156,928			9,715,480
Depreciation		691,165		426			-		4,319		-			-			695,910
Interest expense		105,811		-			-		224		-			2,599			108,634
Tax expense		-		-			-		-		-			-			-
Capital expenditures for long-lived assets	$	716,491	$	15,350			-	$	52,674	$	-		$	-		$	784,515

	Environmental Services			Cannabinoid Drug Development			Corporate			Total
	For the three months ended June 30, 2022
	Environmental Services			Cannabinoid Drug Development			Corporate			Total

Revenue	$	639,359		$	-		$	-		$	639,359
Cost of services		574,407			-			-			574,407
Gross profit		64,952			-			-			64,952
Net loss		(39,429	)		(107,823	)		(295,934	)		(443,186	)

Total assets		3,855,184			8,334			1,661,781			5,525,299
Capital expenditures for long-lived assets	$	1,107,833		$	-		$	-		$	1,107,833

	Environmental Services			Cannabinoid Drug Development			Corporate			Total
	For the six months ended June 30, 2022
	Environmental Services			Cannabinoid Drug Development			Corporate			Total

Revenue	$	639,359		$	-		$	-		$	639,359
Cost of services		574,407			-			-			574,407
Gross profit		64,952			-			-			64,952
Net loss		(60,146	)		(233,553	)		(597,461	)		(891,160	)

Total assets		3,855,184			8,334			1,661,781			5,525,299
Capital expenditures for long-lived assets	$	1,107,833		$	-		$	-		$	1,107,833

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

As used in this discussion and analysis and elsewhere in this Quarterly Report, the “Company”, “we”, “us” or “our” refer to Malachite Innovations, Inc., a Nevada corporation.

Cautionary Statement

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Unaudited Condensed Financial Statements and the related notes thereto contained in Part I, Item 1 of this Quarterly Report. The information contained in this Quarterly Report on Form 10-Q is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2022 filed on March 31, 2023, and the related audited financial statements and notes included therein.

Certain statements made in this Quarterly Report on Form 10-Q constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These risks and uncertainties include: general economic and financial market conditions; our ability to obtain additional financing as necessary; our ability to continue operating as a going concern; any adverse occurrence with respect to our business or; results of our research and development activities that are less positive than we expect; our ability to bring our intended products to market; market demand for our intended products; shifts in industry capacity; product development or other initiatives by our competitors; fluctuations in the availability and costs of raw materials required in our drug development process; other factors beyond our control; and the other risks described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 31, 2023.

Although we believe that the expectations and assumptions reflected in the forward-looking statements we make are reasonable, we cannot guarantee future results, levels of activity or performance. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those expressed by any forward-looking statements. As a result, readers should not place undue reliance on any of the forward-looking statements we make in this report. Forward-looking statements speak only as of the date on which they are made. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Company Overview

Malachite Innovations, Inc. (“Malachite”) is a public holding company dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Malachite owns and operates a balanced portfolio of operating businesses focused on developing long-term solutions to environmental, social and health challenges, with a particular focus on economically disadvantaged communities. Malachite takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Malachite seeks to thoughtfully allocate its capital into ventures that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for our shareholders.

Our corporate headquarters is located in Cleveland, Ohio, with additional office locations in Rocklin, California and Fola, West Virginia. As of August 1, 2023, we employed 38 full-time employees and engaged various consultants and professional service firms to provide us with flexible and experienced resources to advance our corporate objectives while maintaining a cost-effective overhead structure. We strive to instill a corporate culture of honesty, integrity and respect while advancing our mission of doing well by doing good.

Operating Business Segments

Our five operating business segments are: (i) Environmental Services, (ii) Biochar Products and Solutions, (iii) Stream Mitigation Banking, (iv) Environmental Security Services, and (v) Cannabinoid Drug Development. The Stream Mitigation Banking segment did not have significant operations in the three months ended June 30, 2023.

Information about our business segments should be read together with “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Environmental Services

In May 2022, the Company acquired Range Environmental Resources, Inc., a West Virginia corporation (“Range Environmental”) and Range Natural Resources, Inc., a West Virginia corporation (“Range Natural” and together with Range Environmental, the “Range Reclamation Entities”). The Range Reclamation Entities provide land reclamation, water restoration and environmental consulting services to mining and non-mining customers throughout the Appalachian region with the goal of returning land to pre-mining conditions or repurposing the land for natural, commercial, agricultural or recreational use. The Range Reclamation Entities’ water restoration services seek to improve rivers, streams and discharges through novel and innovative treatment applications to help customers meet their various regulatory standards and requirements. The Range Reclamation Entities also provide environmental consulting services to customers, typically in connection with land reclamation and water restoration projects, and, as an additional value-add service, sell water treatment chemicals manufactured by third parties to their customers. Range Natural also mines natural resources, including coal, for customers incidental to the reclamation and repurposing of mine sites.

According to the U.S. Energy Information Administration (the “EIA”), the United States had 551 coal mines in 2020, comprised of 370 active mines, 141 idled or closed mines, and 40 new or activated mines. Approximately 82% of those coal mines were located in Appalachia (which comprises the Appalachian Mountains and is commonly known as the cultural region in the Eastern United States stretching from the southern part of New York to the northern parts of Alabama and Georgia). According to the EIA, there were approximately three times as many coal mines in the United States in 2008 (compared to 2020) with approximately 89% located in Appalachia. The precipitous decline in the number of operating coal mines since 2008 is due to various supply, demand and regulatory factors, including a reduction in demand for coal as a source of electricity due to the increased use of natural gas and renewable energy, an increase in coal production costs due to inflation and the dearth of cost-effective locations remaining for mining, and a more stringent and costly regulatory environment, all of which have resulted in an increasingly difficult market for coal producers.

In 2000, coal was responsible for 1,966 billion kWh of electricity generation, which represented 52% of the total electricity generation in the United States. However, in 2022, coal was responsible for only 828 billion kWh of electricity generation, which represented 20% of the total electricity generation in the United States. According to the EIA, 23% of the 200,568 megawatts of coal-fired capacity currently operating in the United States is scheduled to retire by the end of 2029 due to the high cost of operations, continued competition from natural gas and renewable energy resources, and sustainable initiatives of energy producers.

However, the reclamation of closed and inactive mine sites has not kept pace with the increase in closed and idled mine sites, thus creating a substantial backlog of reclamation work that needs to be completed on former mine sites. According to the U.S. Office of Surfacing Mining Reclamation and Enforcement (“OSMRE”), there are approximately 50,000 high-priority abandoned mine land locations in the United States resulting from legacy coal mining operations that failed to adequately reclaim the land and waterways back to their natural state. Additionally, there are tens of thousands of active mine sites in the United States that require contemporaneous reclamation of land and waterways during the active mining process, and an estimated equally large number of idled mine locations that also require significant land reclamation and water restoration services.

Under the Surface Mining Control and Reclamation Act of 1977 (“SMCRA”), OSMRE was established for two basic purposes: (i) to ensure coal mines in the United States operate in a manner that protects citizens and the environment during mining operations and to restore the land to beneficial use following mining, and (ii) to implement an Abandoned Mine Land (“AML”) reclamation program to address the hazards and environmental degradation resulting from two centuries of coal mining activities that occurred before SMCRA was passed in 1977. The AML reclamation program is funded through fees levied against coal producers based on tons of coal produced. As of September 2020, the AML reclamation fund had collected a total of $11.7 billion in coal mining fees over the life of the program, with $9.5 billion (81%) appropriated and distributed in accordance with SMCRA, and $2.2 billion (19%) unappropriated and available for future disbursement. In November 2021, the Infrastructure Investment and Jobs Act was enacted, which, among other things, authorized $11.3 billion in new funding to be appropriated for deposit into the AML reclamation fund. Importantly, the AML reclamation fund is only available to help fund the reclamation of mines abandoned before SMCRA was enacted in 1977; therefore, all mines abandoned after the year 1977 cannot access funding from the AML reclamation fund and must obtain funding from other sources.

Additionally, each state in Appalachia has a Department of Environmental Protection (“DEP”) or an equivalent agency that oversees coal mining permitting, operations, and reclamation. Under DEP rules and regulations, coal mining companies are required to develop a mining and reclamation plan that is approved by the applicable state agency, obtain a mining permit from the state, and secure a reclamation surety bond from a qualified third-party insurance company or provide a comparable financial guarantee. The reclamation surety bond provides the state with financial assurances that land reclamation and waterway restoration will be performed in accordance with the original reclamation plan once mining is complete if the coal mining company, as primary obligor, fails to perform. Therefore, there are at least three groups who may need land reclamation, water restoration and environmental auditing services: (i) mining companies when permits are active and reclamation bonds are not in default, (ii) surety bond insurers when reclamation bonds are in default, and (iii) states through their AML reclamation funds for mine lands abandoned before 1977 and for mine lands with defaulted coal mining companies and surety bond insurers after 1977.

At the time of acquisition in May 2022, the Range Reclamation Entities had one reclamation customer, 15 pieces of owned and financed equipment, eight pieces of leased equipment, and 12 employees, all located and operating in West Virginia. As of June 30, 2023, approximately one year later, the businesses had four reclamation customers, 60 pieces of owned and financed equipment, and 29 employees in West Virginia. For the full year 2021, the Range Reclamation Entities had revenues of approximately $2.5 million. For the partial year period from May 11, 2022 to December 31, 2022, the Range Reclamation Entities had revenues of approximately $4.8 million. For the first six months of 2023, the Range Reclamation Entities had revenues of approximately $6.9 million. The Range Reclamation Entities have also made a significant investment in recruiting, retaining and rewarding employees, including providing new benefits such as health insurance, paid time off, vacation days, 401K retirement plan, and job advancement training. The Range Reclamation Entities’ employees are their most valuable asset, and therefore we are committed to building a best-in-class culture and financially rewarding our talented, hard-working employees so that we can maximize the good we can do for our people and their families.

The Range Reclamation Entities are planning for continued growth in their land reclamation, water restoration and consulting businesses by expanding their market share with existing coal mining customers reclamation bond insurers, and the DEP of each state in Appalachia for AML projects, adding new coal mining and non-coal mining customers, and collaborating with the Company’s other operating businesses to generate incremental sales opportunities. We will seek to add additional people, equipment and technologies to support these ambitious growth goals to ensure we successfully execute our value creation plans for the Company and our shareholders.

Biochar Products and Solutions

Terra Preta, Inc., an Ohio corporation (“Terra Preta”), is a biochar product development and environmental solutions business started by the Company in December 2022. Terra Preta is developing a novel and innovative combination of biochar, proprietary materials and structural designs intended to create several first-of-its-kind agricultural and water filtration products and solutions.

Biochar is a solid, lightweight carbon-rich material produced by the thermal decomposition of organic material (such as cellulosic feedstock, including wood and plants) using a chemical-conversion process known as pyrolysis. Carbonization pyrolysis is a chemical degradation process that heats organic materials to produce carbon-rich biochar, liquid bio-oils, and syngas products. Since organic material is thermally decomposed without oxygen during the pyrolysis process, combustion does not occur, so the process allows for the permanent capture of carbon in the biochar end-product and eliminates the release of climate-damaging carbon dioxide into the atmosphere. The specific yield of biochar during the carbonization pyrolysis process depends on several variables such as temperature, heating time and heating rate. Lower temperatures, longer heating times and lower heating rates typically yield more biochar and less bio-oil and syngas.

Terra Preta has been launched to build a full-cycle, carbon-negative business that reduces greenhouse gases from the atmosphere, passively filters contaminated water without the use of harsh chemicals, and provides a fortified, nutrient-rich soil amendment to improve the growth of agricultural products.

Greenhouse gases, comprised of carbon dioxide, methane, nitrous oxide and fluorinated gases, are gases that trap heat in the atmosphere, and are generally believed to result in warmer temperatures and climate change, including changing weather patterns, rising sea levels, and more extreme weather events. Carbon dioxide enters the atmosphere through, among other things, the burning of fossil fuels, solid waste and other biomass materials, and is removed from the atmosphere when absorbed by plants during the photosynthesis process. Terra Preta is in discussions with a large affiliated landowner to enter into a long-term lease or purchase of at least 100 acres of former mine land in West Virginia for the planting, growth and harvesting of crops to serve as the primary feedstock for our biochar production operations. The newly planted crops would then act as a “carbon sink”, drawing substantial amounts of carbon dioxide from the atmosphere into the plants through the photosynthesis process. When the plants are harvested, biochar is produced through the carbonization pyrolysis process and the captured carbon dioxide is permanently preserved as carbon in the biochar product for use in water treatment and agricultural end uses.

Pursuant to rules adopted under the Clean Water Act of 1972 (“Clean Water Act”), the U.S. Environmental Protection Agency (“EPA”) has implemented various pollution control programs such as wastewater standards for industry and recommendations for pollutants in surface waters. The Clean Water Act prohibits any party from discharging pollutants into a water of the United States unless they have a permit issued under the National Pollutant Discharge Elimination System (“NPDES”), which contains limits on what a party can discharge and establishes monitoring and reporting requirements. On mining sites, coal operators are required to sample and test their water discharges on a regular basis to ensure compliance with the Clean Water Act and applicable NPDES permits. Currently, most mining operators treat non-compliant water with temporary holding ponds and expensive chemicals such as pH adjusters, coagulants and flocculants that require constant reapplication to ensure compliance. Terra Preta will focus on developing a proprietary, biochar-based passive treatment system that treats non-compliant mine site discharges to ensure compliance with the Clean Water Act and NPDES permits without the need for holding ponds or expensive chemicals.

Sustainable agriculture plays a critical role in the stability, growth, and diversification of our future food supply chain and the growth of plants intended to serve as a carbon sink to reduce greenhouse gases. High-quality soil, a key condition for sustainable agriculture, requires organic matter, microorganisms, nutrients, and optimal compaction. Subsoils with a sufficient number of air-filled pores have little restriction to drainage and aeration, and typically are able to decompose and cycle organic matter and nutrients more efficiently. Alternatively, soil with poor aeration leads to the build-up of carbon dioxide, reduces the ability of plants to absorb water and nutrients, and leads to increased plant stress and root disease. To help address the ill effects of soil compaction, Terra Preta is developing a proprietary, fortified biochar soil amendment that provides unique soil structuring characteristics that will allow plants to grow strong roots that optimize the absorption of water and nutrients, thereby reducing root stress and disease.

In December 2022, Terra Preta filed trademarks for biochar goods and services related to agricultural and water treatment applications. In March 2023, Terra Preta filed provisional patents related to novel and innovative agricultural and water treatment solutions and designs. Additionally, in March 2023, Terra Preta purchased two pyrolysis ovens that each produce one ton of biochar per day to advance our research and development activities. We anticipate that several biochar-based water filtration and soil amendment products will be available for production and sale by the end of 2023.

Stream Mitigation Banking

In December 2022, the Company formed Pristine Stream Ventures, Inc., an Ohio corporation (“Pristine Stream”) to engage in the business of establishing “mitigation banks” throughout the Appalachian region in order to restore and preserve environmentally degraded streams and waterways and support new economic development, with a particular focus on coal mine sites in economically disadvantaged areas that are being repositioned for next generation industries and job creation.

A mitigation bank is a stream, wetland or other aquatic resource that has been restored or preserved for the purpose of providing compensation for environmental impacts to other aquatic resources. A mitigation bank is created to ensure that ecological loss resulting from new development is offset by the restoration and preservation of other nearby natural habitats so there is no net loss to the environment. Regulatory agencies determine the number of mitigation credits that a mitigation bank may earn and sell upon the completion of each specific restoration project, and likewise, the number of mitigation credits that a developer is required to purchase to offset the environmental impact of the new development project.

Under Section 404 of the Clean Water Act, a permit from the U.S. Army Corps of Engineers (“Army Corps”) is required to begin a new development that impacts a wetland, stream or other aquatic resource. The Army Corps, following the guidance set forth by the EPA, will grant a permit if the applicant: (i) takes all practicable steps to avoid an adverse impact to a wetland, stream, or other aquatic resource, (ii) minimizes unavoidable damage to a wetland, stream, or other aquatic resource, and (iii) compensates for permanent destruction of a wetland, stream, or other aquatic resource by creating a new comparable aquatic resource, or by restoring a degraded one.

When a wetland, stream or aquatic resource is permanently destroyed as part of a project, the developer must either restore or preserve a new wetland, stream or aquatic resource, or purchase available credits from a qualified and approved mitigation bank that has already restored or preserved a wetland, stream or aquatic resource in a qualifying hydrological unit code (“HUC”) zone. The United States Geological Survey created HUC zones based on a hierarchical land area classification system incorporating surface hydrological features in a standard, uniform graphical framework. HUC zone requirements are used to ensure a restored waterway is proximally located to an impacted waterway so that the no net-loss principle incorporates a geographic factor.

Compensatory mitigation can be accomplished through three options approved by the Army Corps: (i) the developer purchases appropriate credits from an approved mitigation bank, (ii) the developer pays into an approved in-lieu fee fund, or (iii) the developer performs the requisite amount of aquatic restoration. The Army Corps determines, on a case-by-case basis, the appropriate compensation option and amount of compensation mitigation required by a developer to off-set unavoidable adverse effects to the aquatic environment. In determining the amount of compensation mitigation, the Army Corps will consider the functional loss at the development site, the expected functional gain at the mitigation site, the net loss of aquatic resource surface area, risk and uncertainty of the mitigation project, and loss of natural habitat.

Pristine Stream is planning to establish mitigation banks throughout the Appalachian region to earn mitigation credits which Pristine Stream would later sell to developers to allow them to offset the impact of development activities in similar geographical areas. Pristine Stream plans to identify and select qualifying aquatic sites, work closely with applicable federal and state regulatory agencies, and use the Range Reclamation Entities to repair and restore damaged waterways to earn mitigation credits that can be sold by Pristine Stream. Pristine Stream is currently analyzing the supply and demand dynamics of many HUC zones throughout the Appalachian region to determine the optimal areas of focus for its new mitigation banks, and anticipates initiating its first mitigation banking project in Appalachia by the end of 2023.

Environmental Security Services

Range Security Resources, Inc., an Ohio corporation (“Range Security”), is an environmental security services business started by the Company in November 2022. Range Security is focused on providing eco-friendly, technology-driven security services to active and former mine sites, with a particular focus on locations transitioning from coal mining to next generation industries. Range Security is intended to serve as a complementary business to the Range Reclamation Entities.

Mine sites in the Appalachian region frequently comprise thousands of acres of natural habitat with valuable infrastructure and operating assets disbursed across large tracts of land. However, many of these mine sites lack adequate broadband access or cellular service, and therefore traditional technology-based security solutions are not available. Also, due to the large land areas and often challenging access roads and mountainous terrain, consistent visual confirmation of the safety and security of high value assets is problematic, and unnecessary amounts of carbon dioxide are emitted from heavy-duty trucks used to perform frequent visual security checks. Furthermore, due to the remoteness and lack of technological options, most security services in the market fail to provide an independent verification of the security status of a mine site and confirmation of visual security checks, resulting in a customer’s uncertainty regarding the actual security services being provided.

Valuable assets commonly found on mine sites requiring high-levels of security services include office buildings, coal operation facilities such as preparation plants and loadout facilities, power stations and electrical lines, vehicles and heavy equipment, supplies and chemicals, and spare parts and components. These high-value assets are frequently the target of theft since all or parts of these assets can be easily removed from the mine site and sold for cash. Unfortunately, the actual damage to the operation resulting from this type of destructive theft is frequently many times the market value of the stolen item, primarily due to the losses resulting from the down-time of operations, the cost of repairs and replacement components, and the long-term damage to critical infrastructure that can be repurposed and used to attract next generation industries once the mining is complete.

In March 2023, Range Security was engaged by its first customer for environmental security services covering a 13,000-acre coal mine site in West Virginia. Range Security has hired seven new security professionals, and is focusing its recruitment efforts on military veterans, police officers, and other professionals with security experience. Range Security has purchased two fuel-efficient utility task vehicles for ground surveillance and a thermal-imaging drone for aerial surveillance, all of which use significantly less fuel and electricity to operate than traditional security vehicles and provide a much broader coverage range with a substantially lower carbon footprint. Range Security is also in the process of establishing satellite-based wireless service to support video surveillance and enable a mobile technology solution used by our security professionals to provide real-time evidence of visual security checks. Range Security plans to expand its security service business onto several additional mine sites prior to the end of 2023, with a particular focus on locations with valuable infrastructure being repurposed into non-coal multi-use complexes with attractive job growth prospects and next generation industry opportunities.

Cannabinoid Drug Development

Graphium Biosciences, Inc., a Nevada corporation (“Graphium”), is a cannabinoid-based drug development company tracing its history of technological innovation and drug advancement back to October 2011 through two predecessor entities, Stevia First Corp. and Vitality Biopharma, Inc. In October 2021, the Company formed Graphium as a wholly-owned subsidiary and transferred all of its drug development assets to this newly-formed entity.

Graphium is advancing a broad portfolio of glycosylated cannabinoid prodrugs that have been developed to unlock the rebalancing effects of the endocannabinoid system to address numerous chronic conditions with inadequate pharmaceutical options. Graphium’s leading drug candidate, VBX-100, is a glycosylated tetrahydrocannabinol (“THC”) cannabinoid that targets inflammatory conditions of the gastrointestinal tract but without unwanted psychoactive or intoxicating side effects.

Cannabinoids, including THC and cannabidiol (“CBD”), have well-known therapeutic benefits through their interaction with the human endocannabinoid system, which serves a regulating and rebalancing function in the body. For decades, patients have used cannabinoids to activate the endocannabinoid system to provide relief for numerous chronic and debilitating ailments, including inflammation, pain, anxiety, depression, and cancer. However, THC, a commonly-used cannabinoid with significant therapeutic benefit, is psychoactive and intoxicating, and therefore its use has many practical, and in some cases legal, limitations. Nevertheless, many patients with chronic health conditions, including gastrointestinal inflammation, continue to use cannabinoids because current pharmaceutical offerings do not provide adequate therapeutic relief or result in unwanted side effects.

Our novel scientific discovery was the development of a proprietary enzymatic bioprocessing technology that adds one or more glucose molecules to a cannabinoid, resulting in our proprietary glycosylated cannabinoid compounds. Our glycosylated cannabinoids act as prodrugs that achieve targeted delivery of the bioactive cannabinoids within the body once they are activated. Prodrugs are compounds that, after administration, are metabolized into a pharmacologically active drug and are often designed to improve drug properties and reduce known or expected toxicities and adverse side effects. The advantages of our glycosylated cannabinoid prodrugs may include: (i) administration in a convenient oral formulation, (ii) targeted delivery with release in the colon or large intestine, (iii) improved stability with limited degradation or drug metabolism, and (iv) delayed release enabling longer-lasting effects and fewer administrations by patients.

We have learned through our animal studies that glucose bound to cannabinoid molecules are inactive and poorly absorbed from the intestines, allowing the combined molecule to reach the large intestine where glycoside hydrolase enzymes cleave the glucose and the cannabinoid is released in a targeted and restricted manner. Further, we have learned through our animal studies that a targeted release of THC, which could be provided in very low doses to achieve physiologically beneficial results, serves as an anti-inflammatory agent in the lower gastrointestinal tract and minimizes the amount of THC absorbed into the blood stream. Therefore, we anticipate our glycosylated cannabinoid prodrug will provide the anti-inflammatory benefits of low-dose THC while avoiding the psychoactive and intoxicating properties that hinder the broader pharmaceutical use of THC. Initially, we are targeting the $20 billion inflammatory bowel disease (“IBD”) market in the United States, which is composed of patients suffering from ulcerative colitis and Crohn’s disease, both chronic and debilitating conditions with no cure. We also believe our glycosylated cannabinoids could also be used to treat other indications, including, among others, irritable bowel syndrome (“IBS”), anxiety, depression, autism and cancer.

By using our proprietary enzymatic bioprocessing technologies, our research team has developed a novel family of over 100 glycosylated cannabinoid prodrugs. These glycosylated cannabinoids have unique commercial applications and patentable compositions of matter, which are separate and distinct from ordinary cannabinoids. Currently, our intellectual property is comprised of the following patents: (i) Cannabinoid Glycoside Prodrugs and Methods of Synthesis: Patent filed in 2016 and granted in 2021 for the invention of novel glycosylated cannabinoids and methods of targeted delivery for the treatment of gastrointestinal disorders, including IBD and IBS, (ii) Antimicrobial Compositions Comprising Cannabinoids and Methods of Using the Same: Patent filed in 2018 and granted in 2021 for the use of cannabinoids as antibiotics for the treatment of Clostridioides difficile, (iii) Novel Cannabinoid Glycosides and Uses Thereof: Patent filed in 2020 and in prosecution for additional novel cannabinoid glycosides and includes research data supporting the improved characteristics and commercial production strategies for these new molecules, and (iv) Continuous Enzymatic Perfusion Reactor System: Patent filed in 2021 and in prosecution for our improved reactor system for the efficient enzymatic glycosylation of hydrophobic small molecules, including cannabinoids. We believe our intellectual property portfolio of glycosylated cannabinoids possess significant value and, as a result, we have allocated substantial resources to ensure that our U.S. and international patents are properly filed and successfully prosecuted. As our research efforts involving glycosylated cannabinoids continue to progress, we plan to file additional patents to further expand our growing family of intellectual property assets and create long-term value for our shareholders.

Our research team has performed 23 animal studies to test the safety, efficacy and dosing levels of our glycosylated cannabinoids, which have provided us with favorable scientific data and the opportunity to further refine our drug development plan. We have performed two industry standard colitis disease mouse models: (i) TNBS model in 2017 and 2018 that generated favorable colitis prevention data, and (ii) DSS model in 2021 that generated favorable colitis treatment data. In 2021, we received a letter from the Food and Drug Administration’s (“FDA”) Office of Orphan Products Development stating that we have been granted Orphan Drug Designation for our glycosylated cannabinoid VBX-100 for the treatment of pediatric ulcerative colitis. An Orphan Drug Designation provides several benefits, including fee waivers, tax credits, fast tracking of regulatory processes, and seven years of market exclusivity.

Due to our development of pharmaceutical products, we are subject to extensive regulation by the FDA and other federal, state, and local agencies. Also, since we are researching and developing cannabinoid-based products, we are subject to regulation by the U.S. Drug Enforcement Administration (“DEA”). Our research and development activities focus on cannabinoids, particularly THC and CBD derived from the cannabis plant, which the DEA has classified as Schedule I substances. Schedule I substances are defined as drugs with no currently accepted medical use and a high potential for abuse. In May 2019, the DEA informed us that it had determined that they consider our VBX-100 prodrug a Schedule I substance. As a result, any developing, testing, manufacturing, or clinical studies involving our VBX-100 prodrug, and by inference potentially all of our THC-glycoside molecules, are required to be properly licensed by the DEA and adhere to strict diversion control standards.

We are working closely with a third-party contract research organization to develop a detailed drug development plan to advance our leading drug candidate, VBX-100, through Phase II clinical trials by the end of 2025, subject to receipt of sufficient funding, which is currently estimated to be approximately $12.0 million. The Company is actively seeking to raise the necessary funding to advance our leading drug candidate, VBX-100. If we are successful in raising the necessary capital and advancing VBX-100 through Phase II clinical studies, then we would seek to maximize shareholder value by either selling our drug development assets to a strategic purchaser or raising additional capital to advance VBX-100 through Phase III clinical trials.

Impact Investing Strategy

Our impact investing strategy aims to improve the health and wellness of people and the planet, while also generating long-term sustainable financial returns for our shareholders. We believe that doing well and doing good are not mutually exclusive, and that an impact investing strategy can balance the environmental, social and economic needs of people and the planet while also generating attractive risk-adjusted financial returns for shareholders.

Our impact investing strategy provides an opportunity for our dedicated team to address pressing environmental, social and economic challenges, such as climate change, air and water pollution, educational inequality and economic disparity, through the development of technology-based solutions. By actively directing investment capital towards businesses that are working to create positive environmental, social and economic outcomes, our impact investing strategy can meaningfully contribute to an improved people-planet ecosystem and a healthier and happier way of life.

We have a particular interest in providing environmental and social solutions in economically-disadvantaged regions of the United States. Initially, the Company is targeting the Appalachian region, which is home to communities with some of the most disadvantaged income, education and employment demographics in the United States. Our ambitious strategy is to allocate investment capital and build operating businesses that provide positive environmental and social impact in the disadvantaged coal communities of Appalachia to maximize the good we can do for people and the planet.

Impact Investing Process

Our Company maintains a rigorous investment process comprised of sourcing, underwriting, acquiring or originating, growing, and exiting impact investing opportunities. Our executive management team is responsible for the construction, execution, and continued refinement of our impact investing process, which relies upon the decades of experience of our executive management team and a periodic review, evaluation and adoption of best practices employed in the direct investment and private equity industry.

Our impact investing process starts with identifying and evaluating potential investment opportunities. We use a variety of sources to identify potential impact investments, including our extensive network of industry contacts, third party intermediaries and proprietary research performed by our executive management team. Each potential impact investment is evaluated based on its fit with our corporate strategy, the individual risks and opportunities of each potential investment, and any synergies with our other impact investments (“Portfolio Companies”). This detailed due diligence review is aimed at identifying and addressing material investment risks and opportunities to create long-term sustainable value for our shareholders. Furthermore, our evaluation of each potential impact investment incorporates, to the extent appropriate, consideration of environmental, social and governance (“ESG”) and diversity, equity and inclusion (“DEI”) factors in the investment decision-making process.

Our impact investments are commonly structured as stock or asset acquisitions with transaction consideration in the form of cash and the Company’s common stock so the former owners of impact investment acquisitions are properly aligned with our public shareholders in the creation of future value. Additionally, the Company has developed innovative business projects that fit within our corporate strategy and have been allocated capital and resources to grow and increase shareholder value. Each such organic innovation has been developed within a newly-created, wholly-owned Portfolio Company (e.g., Terra Preta, Pristine Stream and Range Security) so the executive management team can properly monitor the performance of each organic innovation and optimize the allocation of capital and management resources to maximize the positive overall impact to the Company and its shareholders.

After a potential impact investment is acquired, or an organic innovation is launched, our executive management team is responsible for closely monitoring on a regular basis the performance of each investment. Each Portfolio Company has an experienced management team that is responsible for executing a value creation plan with active support, collaboration and input from the Company’s executive management team. Our complementary hybrid approach to investment management enables the management teams of each Portfolio Company to manage the daily operations of the business in a decentralized manner, while the executive management team of the Company serves as an active collaborator to the management team of each Portfolio Company to ensure the value creation plan is being successfully executed and cross-pollination of ideas, capabilities and synergies are achieved across each Portfolio Company. We believe a balanced approach to individual management and corporate governance provides Portfolio Company management teams with the freedom and autonomy to preserve their ownership mindset while also providing the Company’s executive team with the optimal level of involvement in order to maximize the overall benefits to the Company’s shareholders.

As the value creation plan is executed for each Portfolio Company, the Company’s executive team, in consultation with the management team of each Portfolio Company, will regularly evaluate the strategic options for the business, which could include additional investment to fund strategic growth and expansion, maximizing current cash flow without further investments, or a potential exit to a strategic or financial buyer. This process of evaluating strategic options is dynamic and involves many considerations, including an evaluation of the current and future market conditions, the Portfolio Company’s current and future financial performance, changes in the Portfolio Company’s competitive advantages, macro and micro market conditions, and exit valuations. Since the Company is structured as a perpetual investment vehicle without predetermined hold periods, our executive management team possesses the flexibility to regularly evaluate the risk-return profile of each Portfolio Company and make strategic decisions that maximize the investment returns and value creation for the Company’s shareholders.

Structure and Operation

The Company is organized as a public holding company. Currently, all Portfolio Companies are wholly-owned subsidiaries of the Company and are consolidated in our financial reporting.

The Company’s executive management team works closely with the management team of each Portfolio Company on strategy, operations and financial matters. The Company allocates the time and resources of several executives to support the operations of Portfolio Companies, including accounting, insurance and human resources, to recognize operational efficiencies and cost savings resulting from the Company’s larger scale.

Environmental, Social and Governance

ESG principles are central to our mission of improving the health and wellness of people and the planet. Our impact investing strategy is dedicated to pursuing opportunities that improve the long-term sustainability of our people-planet ecosystem, reverse the damaging effects of climate change, and revitalize disadvantaged communities into next generation cities. We believe that considering ESG principles, along with the profit potential of an investment, enables our team to take a broader, more holistic approach to capital deployment by considering a wide range of stakeholders, including shareholders, the environment and local communities.

We believe our genuine commitment to ESG principles, which is at the heart of our impact investing strategy, truly differentiates our Company from other businesses whose dedication to ESG principles is more peripheral. We believe our strong commitment to ESG principles will allow us to attract similarly-committed customers, suppliers, employees, financial partners, and federal, state and local partnerships who are motivated by our shared sense of purpose and commitment to doing well by doing good.

Diversity, Equity and Inclusion

Our employees are integral to fostering a culture of honesty, integrity and respect. We believe hiring, training, motivating and retaining talented individuals is critical to the successful execution of our impact investing strategy. Our employees are our single most important asset.

We seek to attract employees with different backgrounds and unique perspectives, and provide a safe environment for them to collaborate in a respectful manner so our Company can benefit from their best collective thinking. We believe a diverse, equitable and inclusive workforce increases innovation and creativity, improves decision making, increases adaptability and flexibility, and improves stakeholder engagement. Additionally, we believe these benefits will ultimately result in greater profits and an increase in long-term shareholder value.

Competition

Our Company is focused on a large and growing marketplace for impact investing and ESG business initiatives, and therefore, is anticipated to face competition from a variety of operating businesses and investment funds who are developing business plans and operating strategies to satisfy the increasing demands of these types of investments in the marketplace. In almost all cases, these competitors are larger and better capitalized operating businesses and investment funds.

Our Company competes on the basis of a number of factors, including access to capital, access to impact investing opportunities, recruitment and retention of key personnel, market share with key customers, and supply relationships with critical vendors. Our ability to continue to compete effectively in our businesses will depend upon our ability to attract new employees and retain and motivate our existing employees.

Information Systems

Since inception, the Company and its subsidiaries have used QuickBooks as its general ledger accounting software. However, given the significant current and anticipated growth of its Portfolio Companies and the need for more robust information for management analysis and decision-making, the Company has decided to transition all of its accounting software services from QuickBooks to Foundation Software.

Foundation Software, founded in Cleveland, Ohio in 1985, is specifically designed for service companies, particularly those in the construction, contracting and reclamation industries. Foundation Software offers the Company several enhanced features critical to the successful execution of its value creation plan, including (i) general ledger accounting, including accounts payable, accounts receivable, inventory and customer billing, (ii) equipment tracking on job sites, maintenance, utilization and depreciation, (iii) employee tracking on job sites, time and materials, utilization, and billing, (iv) job costing and profitability reporting segmented by customers, job types and location, and (v) numerous real-time management dashboard and key performance indicator reports that will allow management to closely monitor the performance of each Portfolio Company and react on a timely basis to business opportunities and issues. Furthermore, Foundation Software will allow the Company and its Portfolio Companies to more readily scale operations and efficiently and cost-effectively support the anticipated growth of each business.

The Company completed converting all of the Company accounting system operations from QuickBooks to Foundation Software during the second quarter of 2023.

Results of Operations

Three Months Ended June 30, 2023 and June 30, 2022

Our revenue during the three months ended June 30, 2023 was $3,998,267 and our gross profit was $845,101 (representing a 21% gross profit margin) compared to revenue during the three months ended June 30, 2022 of $639,359 and gross profit of $64,952 (representing a 10% gross profit margin).

During the three months ended June 30, 2023, we incurred general and administrative expenses in the aggregate amount of $635,898 compared to $380,326 incurred during the three months ended June 30, 2022 (an increase of $255,572). General and administrative expenses generally include corporate overhead, salaries for administrative and management personnel and other related compensation costs, financial and administrative contracted services, marketing, consulting costs and travel expenses. These costs include the operations of the Range Reclamation Entities, which were acquired in May 2022. The majority of the increase in general and administrative expenses relates to salaries which increased to $257,081 during the three months ended June 30, 2023, as compared to $116,553 during the three months ended June 30, 2022 (an increase of $140,528) as a result of the hiring of additional administrative and management personnel in connection with the expansion of the Company’s business operations.

In addition, during the three months ended June 30, 2023, we incurred research and development costs of $107,444, compared to $107,823 during the three months ended June 30, 2022 (a decrease of $379). These costs consist primarily of the salary of our Chief Science Officer, rent for our Rocklin lab space, patent-related legal fees, and consulting fees.

During the three months ended June 30, 2023, we recorded total net other expense of $64,997 (all of which was interest expense), compared to total net other expense recorded during the three months ended June 30, 2022 of $19,989 (all of which was interest expense). This increase of $45,008 in interest expense during the three months ended June 30, 2023 was attributable to the increased amount of debt used to finance equipment purchased by the Range Reclamation Entities.

Our net income during the three months ended June 30, 2023 was $36,762 compared to a net loss of $443,186 during the three months ended June 30, 2022 (an improvement of $479,948).

Six Months Ended June 30, 2023 and June 30, 2022

Our revenue during the six months ended June 30, 2023 was $7,013,154 and our gross profit was $1,494,103 (representing a 21% gross profit margin), compared to revenue during the six months ended June 30, 2022 of $639,359 and gross profit of $64,952 (representing a 10% gross profit margin).

During the six months ended June 30, 2023, we incurred general and administrative expenses in the aggregate amount of $1,361,946 compared to $698,267 incurred during the six months ended June 30, 2022 (an increase of $663,679). The majority of the increase in general and administrative costs relates to increased salary expense which increased to $431,334 during the six months ended June 30, 2023 as compared to $116,553 during the six months ended June 30, 2022 (an increase of $314,781), legal fees which increased to $207,639 during the six months ended June 30, 2023, as compared to $71,253 during the six months ended June 30, 2022 (an increase of $136,386), and insurance costs, which increased to $312,122 during the six months ended June 30, 2023 as compared to $99,187 during the six months ended June 30, 2022 (an increase of $212,935) as a result of the insurance related to the increases in the equipment assets and the number of employees of the Range Reclamation Entities.

In addition, during the six months ended June 30, 2023, we incurred research and development costs of $213,621, compared to $233,553 during the six months ended June 30, 2022 (a decrease of $19,932). This decrease primarily resulted from a decrease in legal fees related to research and development, offset by an increase in professional fees related to research and development.

During the six months ended June 30, 2023, we recorded total net other expense of $108,634 (all of which was interest expense), compared to total net other expense recorded during the six months ended June 30, 2022 of $24,292 (all of which was interest expense). This increase of $84,342 in interest expense during the six months ended June 30, 2023 was attributable to the increased amount of debt used to finance equipment purchased by the Range Reclamation Entities.

Our net loss during the six months ended June 30, 2023 was $190,098 compared to a net loss of $891,160 during the six months ended June 30, 2022 (an improvement of $701,062).

Liquidity and Capital Resources

We have incurred losses since inception resulting in an accumulated deficit of $50,402,952.

As of June 30, 2023, we had total current assets of $2,809,964, primarily comprised of cash in the amount of $359,564, accounts receivable of $1,273,635 and unbilled receivables of $1,129,046. As of June 30, 2023, we had total current liabilities of $3,062,401, consisting of outstanding amounts on our lines of credit of $1,200,000, accounts payable of $772,892 and the current portion of long-term debt of $1,089,509. As a result, on June 30, 2023, the Company had negative working capital of $252,437. At December 31, 2022, the Company had negative working capital of $128,371.

As of June 30, 2023, the Company had long-term assets of $6,905,516, comprised of net equipment assets of $6,134,119, goodwill of $751,421, and deposits of $19,976. As of June 30, 2023, the Company had long-term liabilities of $3,457,814, comprised of long-term debt, net of current portion. As of December 31, 2022, the Company had long-term assets of $6,805,827, comprised of net equipment assets of $6,045,514, goodwill of $751,421, and deposits of $8,892. As of December 31, 2022, the Company had long-term liabilities of $3,738,013, comprised of long-term debt, net of current portion.

Sources of Capital

Based on the Company’s current corporate strategy, we expect our general operating and cannabinoid-based drug development research and development expenses to be substantially offset by revenue generated by the Range Reclamation Entities and Range Security. We do not expect to generate significant operating income or losses over the 12 months following June 30, 2023. Based on the Company’s current cash balance and $800,000 currently available under its revolving credit line, the Company expects to have sufficient funds to operate its business over the next 12 months. The Company expects to generate positive cash flow from its operating businesses other than its Cannabinoid Drug Development business. If additional capital is needed in excess of our current capital resources, we will explore financing options to accelerate the funding and execution of our growth strategy and shareholder value creation plan.

Our estimated total expenditures for the 12-month period ending June 30, 2024 could increase if we encounter unanticipated expenses in connection with operating our business as presently planned. In addition, our estimates of the amount of cash necessary to fund our business may prove to be too low, and we could spend our available financial resources much faster than we currently expect. If we cannot raise the capital necessary to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations. If any of these were to occur, there is a substantial risk that our business would fail.

Until such time as our operating businesses are cash flow positive, we expect to continue funding our operations, at least in part, through equity and debt financings. However, sources of additional funds may not be available when needed, on acceptable terms, or at all. If we issue equity or convertible debt securities to raise additional funds or to fund, in whole or in part, acquisitions in furtherance of our business strategy, our existing stockholders may experience substantial dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. If we incur additional debt, we would incur additional interest expenses, and assuming those loans would be available, it would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as strategic business collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary glycosylated cannabinoid technology or other intellectual property which, in turn, could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Moreover, regardless of the manner in which we seek to raise capital, we may incur substantial costs in those pursuits, including investment banking fees, legal fees and other related costs.

Net Cash Used in Operating Activities

For the six months ended June 30, 2023, net cash used in operating activities was $398,399 compared to net cash used in operating activities of $845,068 for the six months ended June 30, 2022. This decrease of $446,669 was primarily attributable to a decrease in the Company’s net loss of $190,098 during the six months ended June 30, 2023, compared to a net loss of $891,160 during the six months ended June 30, 2022 and an increase of accounts payable of $539,084, offset by an increase in unbilled receivables of $1,129,046 during the six months ended June 30, 2023. Net cash used in operating activities during the six months ended June 30, 2022 consisted primarily of a net loss of $891,160 and an increase of unbilled receivables of $230,929 offset by an increase in accounts payable of $192,628 and a decrease in accounts receivable of $273,412.

Net Cash Used in Investing Activities

During the six months ended June 30, 2023, net cash used in investing activities was $784,515 compared to net cash used in investing activities of $1,842,006 for the six months ended June 30, 2022. Net cash used in investing activities during the six months ended June 30, 2023 consisted of equipment purchases totaling $784,515. Net cash used in investing activities during the six months ended June 30, 2022 consisted primarily of equipment purchases totaling $1,107,833 and cash paid in connection with the acquisition of Range Environmental of $750,000.

Net Cash Provided By Financing Activities

During the six months ended June 30, 2023, net cash provided by financing activities was $1,100,109 compared to net cash provided by financing activities of $4,515,020 for the six months ended June 30, 2022. Net cash provided by financing activities during the six months ended June 30, 2023 consisted of $410,000 received from the issuance of common stock and warrants, proceeds of $383,093 from long-term debt and $1,200,000 from revolving lines of credit, offset by repayments on long-term debt of $893,093. Net cash provided by financing activities during the six months ended June 30, 2022 consisted of $3,000,000 received from the issuance of common stock and warrants, proceeds of $1,015,020 from long-term debt, and $500,000 from a revolving line of credit.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that would be material to stockholders.

Critical Accounting Policies

Our financial statements and accompanying notes included in this report have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) applied on a consistent basis. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from the estimates made by management.

We believe the following critical accounting policies require us to make significant judgments and estimates in the preparation of our consolidated financial statements included in this report:

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. The more significant estimates and assumption by management include, among others, assumptions used in valuing assets acquired in business acquisitions, reserves for accounts receivable, assumptions used in valuing equity instruments issued for services, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ from those estimates.

Business Combinations

Business combinations are accounted for using the purchase method of accounting under ASC 805, “Business Combinations.” This method requires the Company to record assets and liabilities of the businesses acquired at their estimated fair values as of the acquisition date. Any excess of the cost of the acquisition over the fair value of the net assets acquired is recorded as goodwill. Determining the fair value requires management to make estimates and assumptions including discount rates, rates of return on assets, and long-term sales growth rates.

Goodwill

As referenced by ASC 350 “Intangibles- Goodwill and Other” (“ASC 350”), management performs its annual test for goodwill at least annually or more frequently, if impairment indicators arise.

Revenue

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.

Recent Accounting Pronouncements

Please refer to Footnote 1 of the accompanying financial statements for management’s discussion of recent accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We have established disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that information relating to the Company is accumulated and communicated to management, including our principal officers, as appropriate to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2023, and have concluded that our disclosure controls and procedures were effective as of June 30, 2023.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently a party to and our properties are not currently the subject of any material pending legal proceedings the adverse outcome of which, individually or in the aggregate, would be expected to have a material adverse effect on our financial position or results of operations.

Item 1A. Risk Factors

Please refer to the risks described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 31, 2023.

Item 6. Exhibits

Exhibit Number		Description of Exhibit

2.1		Agreement and Plan of Merger, dated September 14, 2011, by and between Stevia First Corp. and Legend Mining Inc. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.1.1		Articles of Incorporation of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.1.2		Certificate of Amendment of Articles of Incorporation of Vitality Biopharma, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on July 19, 2016.)

3.1.3		Articles of Merger, effective October 10, 2011 (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.1.4		Certificate of Change, effective October 10, 2011 (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.2.1		Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.2 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.2.2		Certificate of Amendment of Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on February 7, 2012.)

3.2.3		Bylaws of Malachite Innovations, Inc., effective as of November 10, 2021 (Incorporated by reference to Exhibit 3.2.3 to the registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 15, 2021.)

31.1		Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

32.1		Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†

101.INS		Inline XBRL Instance Document *

101.SCH		Inline XBRL Taxonomy Extension Schema Document *

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase *

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document *

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document *

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document *

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

† Furnished herewith.

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MALACHITE INNOVATIONS, INC.

By:	/s/ Michael Cavanaugh
	Michael Cavanaugh
	Chief Executive Officer
	(Principal Executive Officer)

Date: August 1, 2023

EXHIBIT INDEX

Exhibit Number		Description of Exhibit

2.1		Agreement and Plan of Merger, dated September 14, 2011, by and between Stevia First Corp. and Legend Mining Inc. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.1.1		Articles of Incorporation of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.1.2		Certificate of Amendment of Articles of Incorporation of Vitality Biopharma, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on July 19, 2016.)

3.1.3		Articles of Merger, effective October 10, 2011 (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.1.4		Certificate of Change, effective October 10, 2011 (Incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed with the SEC on October 14, 2011.)

3.2.1		Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.2 to the registrant’s Registration Statement on Form S-1 filed with the SEC on August 6, 2008 (File No. 333-152830).)

3.2.2		Certificate of Amendment of Bylaws of Stevia First Corp. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the SEC on February 7, 2012.)

3.2.3		Bylaws of Malachite Innovations, Inc., effective as of November 10, 2021 (Incorporated by reference to Exhibit 3.2.3 to the registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 15, 2021.)

31.1		Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

32.1		Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†

101.INS		Inline XBRL Instance Document *

101.SCH		Inline XBRL Taxonomy Extension Schema Document *

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase *

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document *

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document *

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document *

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

† Furnished herewith.

* Filed herewith

Exhibit 31.1

CERTIFICATION

I, Michael Cavanaugh, certify that:

	1.	I have reviewed this report on Form 10-Q for the quarterly period ended June 30, 2023 of Malachite Innovations, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 1, 2023

Name:	/s/ Michael Cavanaugh
By:	Michael Cavanaugh
Title:	Chief Executive Officer
	(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION

I, Richard McKilligan, certify that:

	1.	I have reviewed this report on Form 10-Q for the quarterly period ended June 30, 2023 of Malachite Innovations, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 1, 2023

Name:	/s/ Richard McKilligan
By:	Richard McKilligan
Title:	Chief Financial Officer
	(Principal Accounting Officer)

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Michael Cavanaugh, the Chief Executive Officer of Malachite Innovations, Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended June 30, 2023, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

/s/ Michael Cavanaugh
Michael Cavanaugh
Chief Executive Officer
(Principal Executive Officer)

Date: August 1, 2023

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Richard McKilligan, the Chief Financial Officer of Malachite Innovations, Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended June 30, 2023, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

/s/ Richard McKilligan
Richard McKilligan
Chief Financial Officer
(Principal Financial and Accounting Officer)

Date: August 1, 2023

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 01, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-53832
Entity Registrant Name	MALACHITE INNOVATIONS, INC.
Entity Central Index Key	0001438943
Entity Tax Identification Number	75-3268988
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	200 Park Avenue
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Cleveland
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44122
City Area Code	(216)
Local Phone Number	304-6556
Title of 12(b) Security	Common Stock
Trading Symbol	MLCT
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		80,850,148

Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 359,564	$ 442,369
Accounts receivable	1,273,635	981,385
Unbilled receivables	1,129,046
Prepaid expenses	47,719	884
Total current assets	2,809,964	1,424,638
Long-term Assets
Equipment, net of accumulated depreciation	6,134,119	6,045,514
Goodwill	751,421	751,421
Deposits	19,976	8,892
Total long-term assets	6,905,516	6,805,827
Total Assets	9,715,480	8,230,465
Current Liabilities
Accounts payable	772,892	233,808
Current portion of long-term debt	1,089,509	1,319,201
Line of credit	1,200,000
Total current liabilities	3,062,401	1,553,009
Long-term Liabilities
Long-term debt, net of current portion	3,457,814	3,738,013
Total long-term debt	3,457,814	3,738,013
Total liabilities	6,520,215	5,291,022
Stockholders’ Equity
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 80,850,148 and 78,116,814 shares issued and outstanding, respectively	80,850	78,117
Additional paid-in-capital	53,517,367	53,074,180
Accumulated deficit	(50,402,952)	(50,212,854)
Total stockholders’ equity	3,195,265	2,939,443
Total Liabilities and Stockholders’ Equity	$ 9,715,480	$ 8,230,465

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	80,850,148	78,116,814
Common stock, shares outstanding	80,850,148	78,116,814

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues	$ 3,998,267	$ 639,359	$ 7,013,154	$ 639,359
Cost of services	3,153,166	574,407	5,519,051	574,407
Gross profit	845,101	64,952	1,494,103	64,952
Operating expenses:
General and administrative	635,898	380,326	1,361,946	698,267
Research and development	107,444	107,823	213,621	233,553
Total operating expenses	743,342	488,149	1,575,567	931,820
Income (loss) from operations	101,759	(423,197)	(81,464)	(866,868)
Other expenses:
Interest expense	(64,997)	(19,989)	(108,634)	(24,292)
Other income
Total other expenses, net	(64,997)	(19,989)	(108,634)	(24,292)
Net income (loss)	$ 36,762	$ (443,186)	$ (190,098)	$ (891,160)
Earnings per share, basic	$ 0.00	$ (0.01)	$ (0.00)	$ (0.02)
Earnings per share, diluted	$ 0.00	$ (0.01)	$ (0.00)	$ (0.02)
Weighted average number of common shares outstanding:
Weighted average number of shares outstanding, basic	80,519,745	65,406,191	79,324,917	58,466,722
Weighted average number of shares outstanding, diluted	80,519,745	65,406,191	79,324,917	58,466,722

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 51,450	$ 48,707,587	$ (49,140,678)	$ (381,641)
Balance, shares at Dec. 31, 2021	51,450,147
Shares issued for cash	$ 20,000	2,980,000		3,000,000
Shares issued for cash, shares	20,000,000
Net income ( loss)			(891,160)	(891,160)
Shares issued in exchange for Range	$ 5,000	745,000		750,000
Shares issued in exchange for Range, shares	5,000,000
Balance at Jun. 30, 2022	$ 76,450	52,432,587	(50,031,838)	2,477,199
Balance, shares at Jun. 30, 2022	76,450,147
Balance at Mar. 31, 2022	$ 51,450	48,707,587	(49,588,652)	(829,615)
Balance, shares at Mar. 31, 2022	51,450,147
Shares issued for cash	$ 20,000	2,980,000		3,000,000
Shares issued for cash, shares	20,000,000
Net income ( loss)			(443,186)	(443,186)
Shares issued in exchange for Range	$ 5,000	745,000		750,000
Shares issued in exchange for Range, shares	5,000,000
Balance at Jun. 30, 2022	$ 76,450	52,432,587	(50,031,838)	2,477,199
Balance, shares at Jun. 30, 2022	76,450,147
Balance at Dec. 31, 2022	$ 78,117	53,074,180	(50,212,854)	2,939,443
Balance, shares at Dec. 31, 2022	78,116,814
Shares issued for cash	$ 2,733	407,267		410,000
Shares issued for cash, shares	2,733,334
Fair value of vested stock options		35,920		35,920
Net income ( loss)			(190,098)	(190,098)
Balance at Jun. 30, 2023	$ 80,850	53,517,367	(50,402,952)	3,195,265
Balance, shares at Jun. 30, 2023	80,850,148
Balance at Mar. 31, 2023	$ 78,117	53,074,180	(50,439,714)	2,712,583
Balance, shares at Mar. 31, 2023	78,116,814
Shares issued for cash	$ 2,733	407,267		410,000
Shares issued for cash, shares	2,733,334
Fair value of vested stock options		35,920		35,920
Net income ( loss)			36,762	36,762
Balance at Jun. 30, 2023	$ 80,850	$ 53,517,367	$ (50,402,952)	$ 3,195,265
Balance, shares at Jun. 30, 2023	80,850,148

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ 36,762	$ (443,186)	$ (190,098)	$ (891,160)
Adjustments to reconcile net loss to net cash used in operating activities:
Fair value of vested stock options			35,920
Depreciation	341,726		695,910	55,392	$ 395,543
Changes in operating assets and liabilities:
Accounts receivable			(292,250)	273,412
Unbilled receivables			(1,129,046)	(230,929)
Interest accrued but not paid				2,789
Due from shareholder				(250,000)
Prepaid expense and other current assets			(46,835)	3,000
Accounts payable and accrued liabilities			539,084	192,628
Deposits			(11,084)	(200)
Net cash used in operating activities			(398,399)	(845,068)
Cash flows from investing activities:
Equipment purchases			(784,515)	(1,107,833)
Cash acquired in acquisition of Range Environmental Resources				15,827
Cash paid for acquisition of Range Environmental Resources				(750,000)
Net cash used in investing activities			(784,515)	(1,842,006)
Cash flows from financing activities:
Issuance of shares for cash			410,000	3,000,000
Proceeds from long-term debt			383,202	1,015,020
Repayment of long-term debt			(893,093)
Proceeds from line of credit			1,200,000	500,000
Net cash provided by financing activities			1,100,109	4,515,020
Net increase (decrease) in cash and cash equivalents			(82,805)	1,827,946
Cash and cash equivalents - beginning of period			442,369	38,343	38,343
Cash and cash equivalents - end of period	$ 359,564	$ 1,866,289	359,564	1,866,289	$ 442,369
Cash paid during the period for:
Interest			108,634	21,503
Stock issued for acquisition				750,000
Income taxes

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Going Concern

Basis of Presentation

Use of Estimates

Revenue Recognition

Cash and Cash Equivalents

Accounts Receivable

Unbilled Receivables

Equipment

SCHEDULE OF EQUIPMENT

	June 30, 2023		December 31, 2022

Equipment	$	7,422,329	$	6,637,814
Accumulated depreciation		1,288,210		592,300
Net book value		6,134,119		6,045,514
Depreciation expense	$	695,910	$	395,543

Delivery Costs

Delivery costs are classified as cost of sales.

Goodwill

Income Taxes

Leases

Stock-Based Compensation

Basic and Diluted Income (Loss) Per Share

	June 30, 2023		December 31, 2022
Options		9,792,544		9,392,544
Warrants		25,046,669		22,313,335
Total		34,839,213		31,705,879
Anti-dilutive loss per shares		34,839,213		31,705,879

Patents and Patent Application Costs

Research and Development

Fair Value of Financial Instruments

Segments

Recent Accounting Pronouncements

ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES

6 Months Ended

Jun. 30, 2023

Business Combination and Asset Acquisition [Abstract]

ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES

2. ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES


Fair value of assets acquired:
Cash	$	15,827
Accounts receivables		889,919
Property and equipment		628,000
Goodwill		751,421
Total assets acquired		2,285,167
Fair value of liabilities assumed		(785,167	)
Purchase price	$	1,500,000
Cash consideration		750,000
Common stock consideration		750,000
Total purchase price	$	1,500,000
Acquisition transaction costs incurred	$	20,592

Goodwill has an assigned value of $751,421 and represents the value of the Range Reclamation Entities’ brand reputation, customer base and employee relations.

GOODWILL

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL

3. GOODWILL

SCHEDULE OF GOODWILL

	June 30, 2023		December 31, 2022
Environmental Services:
Beginning Balance	$	751,421	$	-
Acquisitions		-		751,421
Adjustments		-		-
Ending Balance	$	751,421	$	751,421

EQUITY

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

EQUITY

4. EQUITY

Issuance of Common Stock and Warrants

STOCK OPTIONS

6 Months Ended

Jun. 30, 2023

Share-Based Payment Arrangement [Abstract]

STOCK OPTIONS

5. STOCK OPTIONS

Stock options issued during the three months ended June 30, 2023 and the three months ended June 30, 2022

No stock options were granted to directors, advisors, and employees during the three months ended June 30, 2022.

A summary of the Company’s stock option activity during the six months ended June 30, 2023 is as follows:

SUMMARY OF STOCK OPTION ACTIVITY

	Shares		Weighted Average Exercise Price
Balance outstanding at December 31, 2022		9,392,544	$	0.54
Granted		400,000		0.18
Exchanged		-		-
Exercised		-		-
Expired		-		-
Forfeited		-		-
Balance outstanding at June 30, 2023		9,792,544	$	0.52
Balance exercisable at June 30, 2023		9,592,544	$	0.53

At June 30, 2023, the 9,792,544 outstanding stock options had no intrinsic value.

A summary of the Company’s stock options outstanding as of June 30, 2023 is as follows:

SCHEDULE OF STOCK OPTION OUTSTANDING

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- Date Stock Price
Options Outstanding, June 30, 2023		3,050,000	$	0.18	$	0.18
		1,150,000	$	0.277	$	0.277
		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		350,834	$	1.50 - 1.95	$	1.50 - 1.95
		597,500	$	2.00 - 2.79	$	2.00 - 2.79
		83,334	$	3.10 - 3.80	$	3.10 - 3.80
		18,334	$	4.00 - 4.70	$	4.00 - 4.70
		9,792,544

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2023 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- Date Stock Price
Options Outstanding and Exercisable, June 30, 2023		2,850,000	$	0.18	$	0.18
		1,150,000	$	0.277	$	0.277
		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		350,834	$	1.50 - 1.95	$	1.50 - 1.95
		597,500	$	2.00 - 2.79	$	2.00 - 2.79
		83,334	$	3.10 - 3.80	$	3.10 - 3.80
		18,334	$	4.00 - 4.70	$	4.00 - 4.70
		9,592,544

WARRANTS

6 Months Ended

Jun. 30, 2023

Warrants

WARRANTS

6. WARRANTS

A summary of warrants to purchase common stock issued during the six months ended June 30, 2023 is as follows:

SCHEDULE OF WARRANTS ACTIVITY

	Shares		Weighted Average Exercise Price
Balance outstanding at December 31, 2022		22,313,335	$	0.61
Granted		2,733,334		0.60
Exercised		-		-
Expired		-		-
Balance outstanding and exercisable at June 30, 2023		25,046,669	$	0.61

At June 30, 2023, the 25,046,669 outstanding stock warrants had no intrinsic value.

LINES OF CREDIT

6 Months Ended

Jun. 30, 2023

Lines Of Credit

LINES OF CREDIT

7. LINES OF CREDIT

LONG-TERM DEBT OBLIGATIONS

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

LONG-TERM DEBT OBLIGATIONS

8. LONG-TERM DEBT OBLIGATIONS

Long-term debt consists of debt on vehicles and equipment, which serves as the collateral. Interest rates range from 3.69% to 9.95% for 2023. The debt matures from 2023 through 2028.

A summary of payments due under the long-term debt by year is as follows:


2023 – due between July 1, 2023 and June 30, 2024	$	1,089,509
2024 – due between July 1, 2024 and June 30, 2025		1,133,938
2025 – due between July 1, 2025 and June 30, 2026		768,744
2026 – due between July 1, 2026 and June 30, 2027		756,993
2027 – due between July 1, 2027 and June 30, 2028		626,976
2028 and later – due on July 1, 2028 and thereafter		171,163
Total long-term debt	$	4,547,323

MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK

6 Months Ended

Jun. 30, 2023

Risks and Uncertainties [Abstract]

MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK

9. MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

10. COMMITMENTS AND CONTINGENCIES

SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

SEGMENT INFORMATION

11. SEGMENT INFORMATION

The five reportable segments that result from applying the aggregation criteria are as follows:

●	Environmental Services – land reclamation, water restoration and environmental consulting services

●	Biochar Products and Solutions - biochar product development and environmental solutions business

●	Stream Mitigation Banking – mitigation banks to restore waterways and support economic development

●	Environmental Security Services – security services on mines transitioning to next generation industries

●	Cannabinoid Drug Development – glycosylated cannabinoid drug development program

The Company had no inter-segment sales for the periods presented.

Summarized financial information concerning the Company’s reportable segments is shown as below:

By Categories

	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total
	For the three months ended June 30, 2023
	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total

Sales	$	3,882,492	$	-			-	$	115,775	$	-		$	-		$	3,998,267
Cost of services		3,092,805		-			-		60,361		-			-			3,153,166
Gross profit		789,687		-			-		55,414		-			-			845,101
Net income (loss)		433,922		(19,116	)		-		37,550		(107,444	)		(308,150	)		36,762

Total assets		9,440,020		15,138			-		94,610		8,784			156,928			9,715,480
Depreciation		338,409		426			-		2,891		-			-			341,726
Interest expense		63,061		-			-		224		-			1,712			64,997
Tax expense		-		-			-		-		-			-			-
Capital expenditures for long-lived assets	$	38,289	$	-			-	$	-	$	-		$	-		$	38,289

	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total
	For the six months ended June 30, 2023
	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total

Sales	$	6,870,979	$	-			-	$	142,175	$	-		$	-		$	7,013,154
Cost of services		5,442,713		-			-		76,338		-			-			5,519,051
Gross profit		1,428,266		-			-		65,837		-			-			1,494,103
Net income (loss)		620,565		(38,280	)		-		20,445		(213,621	)		(579,207	)		(190,098	)

Total assets		9,440,020		15,138			-		94,610		8,784			156,928			9,715,480
Depreciation		691,165		426			-		4,319		-			-			695,910
Interest expense		105,811		-			-		224		-			2,599			108,634
Tax expense		-		-			-		-		-			-			-
Capital expenditures for long-lived assets	$	716,491	$	15,350			-	$	52,674	$	-		$	-		$	784,515

	Environmental Services			Cannabinoid Drug Development			Corporate			Total
	For the three months ended June 30, 2022
	Environmental Services			Cannabinoid Drug Development			Corporate			Total

Revenue	$	639,359		$	-		$	-		$	639,359
Cost of services		574,407			-			-			574,407
Gross profit		64,952			-			-			64,952
Net loss		(39,429	)		(107,823	)		(295,934	)		(443,186	)

Total assets		3,855,184			8,334			1,661,781			5,525,299
Capital expenditures for long-lived assets	$	1,107,833		$	-		$	-		$	1,107,833

	Environmental Services			Cannabinoid Drug Development			Corporate			Total
	For the six months ended June 30, 2022
	Environmental Services			Cannabinoid Drug Development			Corporate			Total

Revenue	$	639,359		$	-		$	-		$	639,359
Cost of services		574,407			-			-			574,407
Gross profit		64,952			-			-			64,952
Net loss		(60,146	)		(233,553	)		(597,461	)		(891,160	)

Total assets		3,855,184			8,334			1,661,781			5,525,299
Capital expenditures for long-lived assets	$	1,107,833		$	-		$	-		$	1,107,833

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Going Concern

Basis of Presentation

Use of Estimates

Revenue Recognition

Cash and Cash Equivalents

Accounts Receivable

Unbilled Receivables

Equipment

SCHEDULE OF EQUIPMENT

	June 30, 2023		December 31, 2022

Equipment	$	7,422,329	$	6,637,814
Accumulated depreciation		1,288,210		592,300
Net book value		6,134,119		6,045,514
Depreciation expense	$	695,910	$	395,543

Delivery Costs

Delivery costs are classified as cost of sales.

Goodwill

Income Taxes

Leases

Stock-Based Compensation

Basic and Diluted Income (Loss) Per Share

	June 30, 2023		December 31, 2022
Options		9,792,544		9,392,544
Warrants		25,046,669		22,313,335
Total		34,839,213		31,705,879
Anti-dilutive loss per shares		34,839,213		31,705,879

Patents and Patent Application Costs

Research and Development

Fair Value of Financial Instruments

Segments

Recent Accounting Pronouncements

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SCHEDULE OF EQUIPMENT

	June 30, 2023		December 31, 2022

Equipment	$	7,422,329	$	6,637,814
Accumulated depreciation		1,288,210		592,300
Net book value		6,134,119		6,045,514
Depreciation expense	$	695,910	$	395,543

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

	June 30, 2023		December 31, 2022
Options		9,792,544		9,392,544
Warrants		25,046,669		22,313,335
Total		34,839,213		31,705,879
Anti-dilutive loss per shares		34,839,213		31,705,879

ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES (Tables)

6 Months Ended

Jun. 30, 2023

Business Combination and Asset Acquisition [Abstract]

SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE


Fair value of assets acquired:
Cash	$	15,827
Accounts receivables		889,919
Property and equipment		628,000
Goodwill		751,421
Total assets acquired		2,285,167
Fair value of liabilities assumed		(785,167	)
Purchase price	$	1,500,000
Cash consideration		750,000
Common stock consideration		750,000
Total purchase price	$	1,500,000
Acquisition transaction costs incurred	$	20,592

GOODWILL (Tables)

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

SCHEDULE OF GOODWILL

	June 30, 2023		December 31, 2022
Environmental Services:
Beginning Balance	$	751,421	$	-
Acquisitions		-		751,421
Adjustments		-		-
Ending Balance	$	751,421	$	751,421

STOCK OPTIONS (Tables)

6 Months Ended

Jun. 30, 2023

Share-Based Payment Arrangement [Abstract]

SUMMARY OF STOCK OPTION ACTIVITY

A summary of the Company’s stock option activity during the six months ended June 30, 2023 is as follows:

SUMMARY OF STOCK OPTION ACTIVITY

	Shares		Weighted Average Exercise Price
Balance outstanding at December 31, 2022		9,392,544	$	0.54
Granted		400,000		0.18
Exchanged		-		-
Exercised		-		-
Expired		-		-
Forfeited		-		-
Balance outstanding at June 30, 2023		9,792,544	$	0.52
Balance exercisable at June 30, 2023		9,592,544	$	0.53

SCHEDULE OF STOCK OPTION OUTSTANDING

A summary of the Company’s stock options outstanding as of June 30, 2023 is as follows:

SCHEDULE OF STOCK OPTION OUTSTANDING

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- Date Stock Price
Options Outstanding, June 30, 2023		3,050,000	$	0.18	$	0.18
		1,150,000	$	0.277	$	0.277
		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		350,834	$	1.50 - 1.95	$	1.50 - 1.95
		597,500	$	2.00 - 2.79	$	2.00 - 2.79
		83,334	$	3.10 - 3.80	$	3.10 - 3.80
		18,334	$	4.00 - 4.70	$	4.00 - 4.70
		9,792,544

SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2023 is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Grant- Date Stock Price
Options Outstanding and Exercisable, June 30, 2023		2,850,000	$	0.18	$	0.18
		1,150,000	$	0.277	$	0.277
		750,000	$	0.30	$	0.30
		2,000,000	$	0.35	$	0.35
		1,664,542	$	0.50	$	0.50
		128,000	$	0.96	$	0.96
		350,834	$	1.50 - 1.95	$	1.50 - 1.95
		597,500	$	2.00 - 2.79	$	2.00 - 2.79
		83,334	$	3.10 - 3.80	$	3.10 - 3.80
		18,334	$	4.00 - 4.70	$	4.00 - 4.70
		9,592,544

WARRANTS (Tables)

6 Months Ended

Jun. 30, 2023

Warrants

SCHEDULE OF WARRANTS ACTIVITY

A summary of warrants to purchase common stock issued during the six months ended June 30, 2023 is as follows:

SCHEDULE OF WARRANTS ACTIVITY

	Shares		Weighted Average Exercise Price
Balance outstanding at December 31, 2022		22,313,335	$	0.61
Granted		2,733,334		0.60
Exercised		-		-
Expired		-		-
Balance outstanding and exercisable at June 30, 2023		25,046,669	$	0.61

LONG-TERM DEBT OBLIGATIONS (Tables)

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

SCHEDULE OF MATURITIES OF LONG TERM DEBT

A summary of payments due under the long-term debt by year is as follows:


2023 – due between July 1, 2023 and June 30, 2024	$	1,089,509
2024 – due between July 1, 2024 and June 30, 2025		1,133,938
2025 – due between July 1, 2025 and June 30, 2026		768,744
2026 – due between July 1, 2026 and June 30, 2027		756,993
2027 – due between July 1, 2027 and June 30, 2028		626,976
2028 and later – due on July 1, 2028 and thereafter		171,163
Total long-term debt	$	4,547,323

SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

SCHEDULE OF FINANCIAL INFORMATION OF REPORTABLE SEGMENT

Summarized financial information concerning the Company’s reportable segments is shown as below:

By Categories

	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total
	For the three months ended June 30, 2023
	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total

Sales	$	3,882,492	$	-			-	$	115,775	$	-		$	-		$	3,998,267
Cost of services		3,092,805		-			-		60,361		-			-			3,153,166
Gross profit		789,687		-			-		55,414		-			-			845,101
Net income (loss)		433,922		(19,116	)		-		37,550		(107,444	)		(308,150	)		36,762

Total assets		9,440,020		15,138			-		94,610		8,784			156,928			9,715,480
Depreciation		338,409		426			-		2,891		-			-			341,726
Interest expense		63,061		-			-		224		-			1,712			64,997
Tax expense		-		-			-		-		-			-			-
Capital expenditures for long-lived assets	$	38,289	$	-			-	$	-	$	-		$	-		$	38,289

	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total
	For the six months ended June 30, 2023
	Environmental Services		Biochar Products and Solutions			Stream Mitigation Banking		Environmental Security Services		Cannabinoid Drug Development			Corporate			Total

Sales	$	6,870,979	$	-			-	$	142,175	$	-		$	-		$	7,013,154
Cost of services		5,442,713		-			-		76,338		-			-			5,519,051
Gross profit		1,428,266		-			-		65,837		-			-			1,494,103
Net income (loss)		620,565		(38,280	)		-		20,445		(213,621	)		(579,207	)		(190,098	)

Total assets		9,440,020		15,138			-		94,610		8,784			156,928			9,715,480
Depreciation		691,165		426			-		4,319		-			-			695,910
Interest expense		105,811		-			-		224		-			2,599			108,634
Tax expense		-		-			-		-		-			-			-
Capital expenditures for long-lived assets	$	716,491	$	15,350			-	$	52,674	$	-		$	-		$	784,515

	Environmental Services			Cannabinoid Drug Development			Corporate			Total
	For the three months ended June 30, 2022
	Environmental Services			Cannabinoid Drug Development			Corporate			Total

Revenue	$	639,359		$	-		$	-		$	639,359
Cost of services		574,407			-			-			574,407
Gross profit		64,952			-			-			64,952
Net loss		(39,429	)		(107,823	)		(295,934	)		(443,186	)

Total assets		3,855,184			8,334			1,661,781			5,525,299
Capital expenditures for long-lived assets	$	1,107,833		$	-		$	-		$	1,107,833

	Environmental Services			Cannabinoid Drug Development			Corporate			Total
	For the six months ended June 30, 2022
	Environmental Services			Cannabinoid Drug Development			Corporate			Total

Revenue	$	639,359		$	-		$	-		$	639,359
Cost of services		574,407			-			-			574,407
Gross profit		64,952			-			-			64,952
Net loss		(60,146	)		(233,553	)		(597,461	)		(891,160	)

Total assets		3,855,184			8,334			1,661,781			5,525,299
Capital expenditures for long-lived assets	$	1,107,833		$	-		$	-		$	1,107,833

SCHEDULE OF EQUIPMENT (Details) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
SCHEDULE OF EQUIPMENT (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Equipment	$ 7,422,329	$ 7,422,329		$ 6,637,814
Accumulated depreciation	1,288,210	1,288,210		592,300
Net book value	6,134,119	6,134,119		6,045,514
Depreciation expense	$ 341,726	$ 695,910	$ 55,392	$ 395,543

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive loss per shares	34,839,213	31,705,879
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive loss per shares	9,792,544	9,392,544
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive loss per shares	25,046,669	22,313,335

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) Segment	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
Net loss	$ (36,762)	$ 443,186	$ 190,098	$ 891,160
Cash used in operating activities			$ 398,399	845,068
Going concern, description			The Company estimates, as of June 30, 2023, that it has sufficient funds to operate the business for 12 months given its cash balance of $359,564, line of credit availability of $800,000, and revenues being generated by the Range Reclamation Entities
Cash and cash equivalents	359,564		$ 359,564		$ 442,369
Line of credit current borrowing capacity	800,000		800,000
Allowances for doubtful accounts receivable	0	0	0	$ 0	0
Accounts receivable	1,273,635		$ 1,273,635		$ 981,385
Bad debt expense	$ 0	$ 0
Equipment estimated useful lives	6 years		6 years
Number of operating segments \| Segment			5

SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE (Details) - USD ($)	1 Months Ended	6 Months Ended
	May 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Cash	$ 15,827
Accounts receivables	889,919
Property and equipment	628,000
Goodwill	751,421	$ 751,421		$ 751,421
Total assets acquired	2,285,167
Fair value of liabilities assumed	(785,167)
Cash consideration			$ 750,000
Acquisition transaction costs incurred	20,592
Range Entities [Member]
Business Acquisition [Line Items]
Goodwill	751,421
Purchase price	1,500,000
Cash consideration	750,000
Common stock consideration	750,000
Total purchase price	$ 1,500,000

ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES (Details Narrative) - USD ($)		1 Months Ended
	Jul. 12, 2022	May 31, 2022	Jun. 30, 2023	Dec. 31, 2022	Oct. 11, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill		$ 751,421	$ 751,421	$ 751,421
Range Entities [Member]
Business Acquisition [Line Items]
Business acquisition, cash consideration		1,500,000
Goodwill		$ 751,421
Share Purchase Agreement [Member] \| Range Entities [Member]
Business Acquisition [Line Items]
Business acquisition, ownership percentage		80.00%
Share Purchase Agreement [Member] \| Jeremy Starks [Member]
Business Acquisition [Line Items]
Business acquisition, ownership percentage					10.00%
Contractual profits interest					10.00%
Share Purchase Agreement [Member] \| Range Entities [Member]
Business Acquisition [Line Items]
Business acquisition, number of shares issued		10,000,000
Business acquisition, cash consideration		$ 1,000,000
Separation Agreement [Member] \| Range Entities [Member]
Business Acquisition [Line Items]
Agreement, description	pursuant to which Justice: a) acknowledged that his employment with the Range Reclamation Entities was terminated for cause effective June 30, 2022; b) returned the 5,000,000 shares of the Company’s common stock that had been issued to him under the terms of the Share Purchase Agreement; c) transferred his 10% interest in each of the Range Reclamation Entities to Daedalus Ecosciences; and d) paid Daedalus Ecosciences cash in an amount of $250,000. As a result, only 5,000,000 of the Company’s common stock issued to the Range Shareholders is considered to have been issued in exchange for 90% of the outstanding common stock of each of the Range Reclamation Entities

SCHEDULE OF GOODWILL (Details) - USD ($)	6 Months Ended	12 Months Ended
SCHEDULE OF GOODWILL (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 751,421
Acquisitions		751,421
Adjustments
Ending Balance	$ 751,421	$ 751,421

GOODWILL (Details Narrative) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	May 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 751,421	$ 751,421	$ 751,421

EQUITY (Details Narrative) - USD ($)		6 Months Ended
EQUITY (Details Narrative) - USD ($)	Apr. 11, 2023	Jun. 30, 2023	Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of stock and warrants		$ 410,000	$ 3,000,000
Two Securities Purchase Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock, shares issued	2,733,334
Sale of stock, price per share	$ 0.15
Warrants issued to purchase stock	2,733,333
Warrant exercise price	$ 0.60
Proceeds from sale of stock and warrants	$ 400,000

SUMMARY OF STOCK OPTION ACTIVITY (Details)	6 Months Ended
SUMMARY OF STOCK OPTION ACTIVITY (Details)	Jun. 30, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Shares Outstanding, Balance \| shares	9,392,544
Weighted Average Exercise Price, Outstanding Balance \| $ / shares	$ 0.54
Shares, Granted \| shares	400,000
Weighted Average Exercise Price, Granted \| $ / shares	$ 0.18
Shares, Exchanged \| shares
Weighted Average Exercise Price, Exchanged \| $ / shares
Shares, Exercised \| shares
Weighted Average Exercise Price, Exercised \| $ / shares
Shares, Expired \| shares
Weighted Average Exercise Price, Expired \| $ / shares
Shares, Forfeited \| shares
Weighted Average Exercise Price, Forfeited \| $ / shares
Shares Outstanding, Balance \| shares	9,792,544
Weighted Average Exercise Price, Outstanding Balance \| $ / shares	$ 0.52
Shares, Balance Exercisable \| shares	9,592,544
Weighted Average Exercise Price, Balance Exercisable \| $ / shares	$ 0.53

SCHEDULE OF STOCK OPTION OUTSTANDING (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	9,792,544	9,392,544
Weighted Average Exercise Price, Outstanding Balance	$ 0.52	$ 0.54
Weighted Average Exercise Price, Granted	$ 0.18
Stock Options One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	3,050,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.18
Weighted Average Exercise Price, Granted	$ 0.18
Stock Options Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	1,150,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.277
Weighted Average Exercise Price, Granted	$ 0.277
Stock Options Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	750,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.30
Weighted Average Exercise Price, Granted	$ 0.30
Stock Options Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	2,000,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.35
Weighted Average Exercise Price, Granted	$ 0.35
Stock Options Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	1,664,542
Weighted Average Exercise Price, Outstanding Balance	$ 0.50
Weighted Average Exercise Price, Granted	$ 0.50
Stock Options Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	128,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.96
Weighted Average Exercise Price, Granted	$ 0.96
Stock Options Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	350,834
Stock Options Seven [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	$ 1.50
Weighted Average Exercise Price, Granted	1.50
Stock Options Seven [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	1.95
Weighted Average Exercise Price, Granted	$ 1.95
Stock Options Eight [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	597,500
Stock Options Eight [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	$ 2.00
Weighted Average Exercise Price, Granted	2.00
Stock Options Eight [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	2.79
Weighted Average Exercise Price, Granted	$ 2.79
Stock Options Nine [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	83,334
Stock Options Nine [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	$ 3.10
Weighted Average Exercise Price, Granted	3.10
Stock Options Nine [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	3.80
Weighted Average Exercise Price, Granted	$ 3.80
Stock Options Ten [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	18,334
Stock Options Ten [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	$ 4.00
Weighted Average Exercise Price, Granted	4.00
Stock Options Ten [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	4.70
Weighted Average Exercise Price, Granted	$ 4.70

SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE (Details)	Jun. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	9,592,544
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.53
Stock Options One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	2,850,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.18
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.18
Stock Options Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	1,150,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.277
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.277
Stock Options Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	750,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.30
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.30
Stock Options Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	2,000,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.35
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.35
Stock Options Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	1,664,542
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.50
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.50
Stock Options Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	128,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.96
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.96
Stock Options Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	350,834
Stock Options Seven [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 1.50
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	1.50
Stock Options Seven [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	1.95
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 1.95
Stock Options Eight [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	597,500
Stock Options Eight [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 2.00
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	2.00
Stock Options Eight [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	2.79
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 2.79
Stock Options Nine [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	83,334
Stock Options Nine [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 3.10
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	3.10
Stock Options Nine [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	3.80
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 3.80
Stock Options Ten [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable \| shares	18,334
Stock Options Ten [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 4.00
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	4.00
Stock Options Ten [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	4.70
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 4.70

STOCK OPTIONS (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
STOCK OPTIONS (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangements by share based payment award options grants in period weighted average exercise price		$ 0.18
Share based compensation arrangement by share based payment award options grants in period gross		400,000
Stock options issued to value		$ 35,920
Stock based compensation expense	$ 35,920
Unamortized cost of outstanding stock-based awards	$ 35,920	$ 35,920
Remaining vesting period	2 years
Stock options outstanding	9,792,544	9,792,544		9,392,544
Stock options, intrinsic value	$ 0	$ 0
Directors and Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of the option grants to employees	$ 400,000
Share based compensation arrangements by share based payment award options grants in period weighted average exercise price	$ 0.18
Options expiration period	5 years
Share based compensation arrangement by share based payment award options grants in period gross	200,000
Expected dividend yield	0.00%
Expected life	5 years
Stock options issued to value	$ 0
Directors and Employees [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility rate	273.24%
Discount rate	1.40%
Directors and Employees [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility rate	273.87%
Discount rate	1.55%
Employees [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of the option grants to employees	$ 71,840
Employees [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of the option grants to employees	$ 35,920

SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Number of Shares, Warrants Outstanding, Beginning Balance \| shares	22,313,335
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance \| $ / shares	$ 0.61
Number of Shares, Warrants Granted \| shares	2,733,334
Weighted Average Exercise Price, Warrants Outstanding, Granted \| $ / shares	$ 0.60
Number of Shares, Warrants Exercised \| shares
Weighted Average Exercise Price, Warrants Outstanding, Exercised \| $ / shares
Number of Shares, Warrants Expired \| shares
Weighted Average Exercise Price, Warrants Outstanding, Expired \| $ / shares
Number of Shares, Warrants Outstanding and Exercisable Ending \| shares	25,046,669
Weighted Average Exercise Price, Warrants Outstanding, Outstanding and Exercisable, Ending Balance \| $ / shares	$ 0.61

WARRANTS (Details Narrative) - Warrant [Member]	Jun. 30, 2023 USD ($) shares
Warrants outstanding \| shares	25,046,669
Warrants intrinsic value \| $	$ 0

LINES OF CREDIT (Details Narrative) - USD ($)	1 Months Ended
LINES OF CREDIT (Details Narrative) - USD ($)	Jun. 30, 2023	Nov. 30, 2022
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,000,000
Line of Credit Facility, Expiration Date		Nov. 30, 2023
Line of Credit Facility, Interest Rate During Period		1.00%
Long-Term Line of Credit	$ 200,000
Secured Debt [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,000,000
Line of Credit Facility, Expiration Date	Jun. 24, 2024
Long-Term Line of Credit	$ 1,000,000
Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	9.25%
Prime Rate [Member] \| Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.25%

SCHEDULE OF MATURITIES OF LONG TERM DEBT (Details)	Jun. 30, 2023 USD ($)
Debt Disclosure [Abstract]
2023 – due between July 1, 2023 and June 30, 2024	$ 1,089,509
2024 – due between July 1, 2024 and June 30, 2025	1,133,938
2025 – due between July 1, 2025 and June 30, 2026	768,744
2026 – due between July 1, 2026 and June 30, 2027	756,993
2027 – due between July 1, 2027 and June 30, 2028	626,976
2028 and later – due on July 1, 2028 and thereafter	171,163
Total long-term debt	$ 4,547,323

LONG-TERM DEBT OBLIGATIONS (Details Narrative)	6 Months Ended
LONG-TERM DEBT OBLIGATIONS (Details Narrative)	Jun. 30, 2023
Debt Instrument [Line Items]
Long term debt, maturity description	The debt matures from 2023 through 2028
Minimum [Member]
Debt Instrument [Line Items]
Long term debt, interest rates	3.69%
Maximum [Member]
Debt Instrument [Line Items]
Long term debt, interest rates	9.95%

MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK (Details Narrative) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue Benchmark [Member] \| Largest Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	94.00%		92.00%
Revenue Benchmark [Member] \| Two Largest Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage		91.00%		91.00%
Accounts Receivable [Member] \| Largest Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage			96.00%
Accounts Receivable [Member] \| Two Largest Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage				93.00%

SCHEDULE OF FINANCIAL INFORMATION OF REPORTABLE SEGMENT (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 3,998,267	$ 639,359	$ 7,013,154	$ 639,359
Cost of services	3,153,166	574,407	5,519,051	574,407
Gross profit	845,101	64,952	1,494,103	64,952
Net loss	36,762	(443,186)	(190,098)	(891,160)
Total assets	9,715,480	5,525,299	9,715,480	5,525,299	$ 8,230,465	$ 5,525,299
Depreciation	341,726		695,910	55,392	$ 395,543
Interest expense	64,997	19,989	108,634	24,292
Tax expense
Capital expenditures for long-lived assets	38,289	1,107,833	784,515	1,107,833
Environmental Services [Member]
Segment Reporting Information [Line Items]
Revenue	3,882,492	639,359	6,870,979	639,359
Cost of services	3,092,805	574,407	5,442,713	574,407
Gross profit	789,687	64,952	1,428,266	64,952
Net loss	433,922	(39,429)	620,565	(60,146)
Total assets	9,440,020	3,855,184	9,440,020	3,855,184
Depreciation	338,409		691,165
Interest expense	63,061		105,811
Tax expense
Capital expenditures for long-lived assets	38,289	1,107,833	716,491	1,107,833
Biochar Products and Solutions [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of services
Gross profit
Net loss	(19,116)		(38,280)
Total assets	15,138		15,138
Depreciation	426		426
Interest expense
Tax expense
Capital expenditures for long-lived assets			15,350
Stream Mitigation Banking [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of services
Gross profit
Net loss
Total assets
Depreciation
Interest expense
Tax expense
Capital expenditures for long-lived assets
Environmental Security Services [Member]
Segment Reporting Information [Line Items]
Revenue	115,775		142,175
Cost of services	60,361		76,338
Gross profit	55,414		65,837
Net loss	37,550		20,445
Total assets	94,610		94,610
Depreciation	2,891		4,319
Interest expense	224		224
Tax expense
Capital expenditures for long-lived assets			52,674
Cannabinoid Drug Development[Member]
Segment Reporting Information [Line Items]
Revenue
Cost of services
Gross profit
Net loss	(107,444)	(107,823)	(213,621)	(233,553)
Total assets	8,784	8,334	8,784	8,334
Depreciation
Interest expense
Tax expense
Capital expenditures for long-lived assets
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of services
Gross profit
Net loss	(308,150)	(295,934)	(579,207)	(597,461)
Total assets	156,928	1,661,781	156,928	1,661,781
Depreciation
Interest expense	1,712		2,599
Tax expense
Capital expenditures for long-lived assets

SEGMENT INFORMATION (Details Narrative)	6 Months Ended
SEGMENT INFORMATION (Details Narrative)	Jun. 30, 2023 Segment
Segment Reporting [Abstract]
Number of reportable segments	5

Malachite Innovations (PK) (USOTC:MLCT)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Malachite Innovations (PK) Charts.

Malachite Innovations (PK) (USOTC:MLCT)
Historical Stock Chart
From Jun 2023 to Jun 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

MLCT Malachite Innovations Inc (PK)

Malachite Innovations Inc (PK) News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

MLCT Malachite Innovations Inc (PK)

Malachite Innovations Inc (PK) News

Your Recent History

Company

Business

Popular

Get The App